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1.1 Amyotrophic Lateral Sclerosis (ALS). 
Amyotrophic lateral sclerosis (ALS; also known as Lou Gehring’s disease) is the most common 
adult-onset motor neuron disease, described for the first time by Jean-Martin Charcot in 1874 1. 
The pathology incidence and prevalence is around 2.5 and 4-6 cases per 100,000 people each year, 
respectively, with a slightly higher incidence of disease in men. The hallmark of this disease is the 
selective degeneration of cortical, bulbar and spinal motor neurons, except for those that control 
the bladder and the eye movement (Fig. 1). This leads to generalised muscle weakness leading to 
progressive paralysis of voluntary muscles until death caused by respiratory failure. The average 
age of onset is 50-55 years with a typical survival time of 3-4 years after diagnosis, but this 
parameter is influenced by age at symptom, clinical presentation, age at respiratory dysfunction 
and nutrition state of the patient 2,3. ALS may present as a predominantly lower motor neuron 
(LMN) form designates progressive muscular atrophy (PMA), a predominantly upper lower motor 
neuron (UMN) form called primary lateral sclerosis (PLS), or more commonly with mixed UMN and 
LMN deficits 4. 
 
Figure 1: Motor neurons selectively affected in ALS. Degeneration of motor neurons in the motor cortex leads to 
clinically apparent signs of upper motor neuron abnormalities. Degeneration of motor neurons in the brain stem and 




Although the majority of cases are classed as sporadic ALS (sALS), approximately 10% of ALS cases 
are inherited (familial ALS, fALS), with multiple autosomal dominant and recessive forms. Sporadic 
and familial ALS share common clinical and neuropathological manifestations, and ALS patients 
show some degree of heterogeneity as far as symptoms, age of onset and disease duration are 
concerned, furthermore all genes found mutated in fALS cases have also been found mutated in 
sALS 5,6. 
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The causes of the majority of ALS cases are still obscure. Although numerous pathological 
mechanisms have been elucidated, ALS remains an invariably fatal disease in the absence of any 
effective therapy. The heterogeneity of the disease and the failure to develop satisfactory 
therapeutic protocols reinforce the view that ALS is a multi-factorial and multi-systemic disease. 
Up to now, Riluzole is the only approved medication as ALS treatment, it has the effect to slow the 
disease in humans but only slightly, prolonging survival by 3 months and not clearly improving the 
quality of life of patients 7. Numerous other treatments are currently in different phases of clinical 
trials and include anti-inflammatories, neurotrophic, anti-oxidants and anti-apoptotic molecules 8. 
1.2 Aetiology of ALS. 
ALS, like many other neurodegenerative diseases, presents an extremely complex aetiology 
determined by environmental and genetic factors. In fact, in most cases to disease development 
contribute both genetic and environmental factors, and only a small percentage of cases can be 
attributed simply one of the two factors. 
The pathogenic mechanisms that underlie ALS remain mostly unclear, even if different alterations 
of cellular function in ALS motor neurons, including protein misfolding, RNA metabolism 
dysfunction, mitochondrial defects, oxidative stress, altered axonal transport, excitotoxicity, 
insufficient growth factor signaling and inflammation have been identified 9,10. Several factors are 
proposed to instigate these phenomena, including various environmental risk factors (for example, 
insecticides, pesticides and cigarette smoking)11,12 latent infections by viral and non-viral agents 13, 
toxins and autoimmune reactions 14. 
Lately there has been rising interest the role played by non-neuronal neighbouring cells in the 
pathogenesis of motor neuron damage. In fact ALS is considered also a glial pathology and 
disruption of glial cells/motoneurons communication contribute to neurodegeneration and the 
propagation of motor neuron injury 15. 
1.2.1 ALS environmental factors. 
Given that sALS represents approximately 90% of all ALS cases, it has been hypothesized that 
exposure to different environmental factors may interact with individual genetic susceptibility 
playing a remarkable role in the pathogenesis of the disease. 
Firstly it was hypothesized that cigarette smoking and many chemicals contains, could contribute 
to ALS development through lipid peroxidation via formaldehyde exposure 11,16. Second it appears 
that life style as well as particular occupation could be associated to ALS for their continued 
exposure to toxic agents. In particular, consumption of food with high concentrations of the 
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neurotoxic aminoacid (β-methyl-amino-L-alanine)17, use of cholesterol-lowering drugs 18, and 
environmental toxicants such as heavy metals 19, pesticides or herbicides 12,20 may be potential 
risk factors. Evidences in several case-control studies as well as in experimental studies showed 
that exposure to these toxicants could induce progressive brain damage by increase of ratio 
between reactive oxygen species (ROS) and reactive nitrogen species (RNS)21, decrease activation 
of astrocytes with neuroprotective effects 22 and inhibition of acetylcholinesterase, resulting in 
excessive stimulation of cholinergic receptors and excitotoxicity 23. Also intensive and strenuous 
physical exercise of professional and amateur football players (Italian and English soccer 
players)24,25 as well as military service (Gulf War veterans in the US Army)26 could represent a risk 
factor for ALS linked to the intermittent occupational hypoxia resulting in the production of ROS27 
or to the repeated head injuries 28. 
In short, as just described over the years a growing list of potential environmental risk factors for 
ALS has been proposed, but at present there is no ascertained causal link between any of them 
and ALS pathogenesis 29. 
Recently, it has been evidenced the involvement of epigenetic factors on the progression of many 
human pathologies, including neurodegenerative diseases such as ALS. The epigenetic 
modifications could provide a possible link between the environmental risk factors and the gene 
expression alterations responsible for the ALS onset 30. In fact, it has been proposed that 
epigenetic silencing of genes important to motor neurons functions could underlie ALS 
development. In support to this hypothesis, it has been shown that treatment with histone 
deacetylase enzymes (HDAC) inhibitors significantly prolong survival, improves motor 
performance and reduce the loss of motor neurons in mouse models of ALS 31,32. 
1.2.2 ALS genetic factors. 
In the last years, there has been a rapid progress in our knowledge of genetic causes for ALS. 
Familial ALS can be inherited as an autosomal dominant or autosomal recessive trait. Up to date, 
more than 20 loci have been identified by genetic analysis, and several have been assigned to 
specific genes (Table 1). 
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Table 1: The genetics of fALS. More than 20-ALS genes have been identified in fALS. These genetic mutations 
represent different molecular pathways of motor neuron degeneration. Abbreviations: AD: Autosomal dominant; AR: 
Autosomal recessive; VAPB: Vesicle associated membrane protein associated protein B; VCP: Valosin Containing 
Protein; SIGMAR1:Sigma Non Opioid Intracellular Receptor; C9ORF72: Chromosome 9 open reading frame 72; DAO:D-




Linkage studies indicated that both types of inheritance are represented by more than one genetic 
entity. The relationship between the genetic subtypes and the pathological subtypes as well as 
clinical phenotype has become more and more clear. Although in many cases the function of 
mutant protein is not yet clearly identified or many different functions have been proposed, the 
available data shows that fALS proteins are involved in several cellular processes, from RNA 
processing to antioxidant response, axonal and vesicular transport and angiogenesis 3,33. 
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1.3 ALS1/Superoxide Dismutase 1 (SOD1). 
1.3.1 Structure and functions. 
Eukaryotic copper, zinc superoxide dismutase (SOD1) is a 32-kDa homodimeric metalloenzyme, 
encoded on chromosome 21 (21q22.1) and found predominantly in the cytosol, but also in the 
mitochondrial intermembrane space, nucleus and peroxisomes. SOD1 is an abundant protein in 
the CNS, accounting for about 1% of brain protein, but it is also ubiquitously expressed in all other 
tissues 34,35. Each subunit of SOD1 forms an eight-stranded -barrel and contains an active site that 
binds a catalytic copper ion (binding residues: His46, His48, His63 and His120), a structural zinc ion 
(binding residues: His63, His71, His80 and Asp83) and a disulphide bond. Through cyclical 
reduction and oxidation (dismutation) of copper, SOD1 converts the superoxide anion to dioxygen 
and hydrogen peroxide preventing the further generation of reactive oxygen species (ROS)36,37,38 
(Fig. 2). 
 
Figure 2: Structure and function of SOD1. A) SOD1 gene position on chromosome 21. B) Tridimensional structure of 
human SOD1. C) Active site of Cu/Zn SOD1. D) Mechanism cyclic oxidation-reduction catalysed by SOD1. 
 
1.3.2 SOD1 mutations. 
About 20% of all fALS and 1-4% of sALS cases carry mutations in the locus ALS1 on chromosome 21 
that codes for SOD1 (Cu, Zn superoxide dismutase 1, OMIM #105400). After the first report in 
1993, more than 150 different mutations have been identified in all five exons of SOD1 
predominantly in missense mutations, but also a small percentage of nonsense mutations, 
insertions and deletions. Most mutations act dominantly except two, N86S and D90A, that are 
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linked to recessive inheritance 39,40 although the former mutation was described in rare juvenile 
onset ALS (Fig.3). 
 
Figure 3: Schematic diagram of human SOD1 primary sequence with exons, introns, metal binding domains (Cu, Zn), 
intramolecular disulphide bond (SH) and mutations linked to sporadic and familial ALS. Mutations are distributed 
throughout all exons with high prevalence in exons 4 and 5. No clear structure–function relationship to fALS appears 





Since some mutations concern the metal binding residues at the active site, while others may 
concern correct folding or stability of the homodimer, the biochemical and biophysical properties 
of ALS-associated mutant SOD1 proteins are rather heterogeneous 42. In fact, studies on 
recombinant mutant SOD1 proteins have been proved that ALS-associated SOD1 mutations can be 
attributed at two mutant classes, the "wild type like" (WTL) SOD1 mutants which retain the ability 
to bind copper and zinc and exhibit normal specific activity, indicate a native-like structure with 
only subtle changes to the backbone fold, in contrast the "metal-binding region" (MBR) SOD1 
mutants that are deficient in copper and zinc and exhibit severe thermal destabilization and 
structural disorder of conserved loops near the metal-binding sites 43. G93A and H80R SOD1 
mutants belong respectively to the two classes of mutants described above. 
There is no clear correlation between enzyme activity, clinical progression and disease phenotype 
44. ALS cases linked to SOD1 mutants show ample variation in the phenotype in the age of onset, 
severity, rate of disease progression and duration. However, patients carrying the A4V missense 
mutation (the most common SOD1 mutation in North America) have shorter survival with death 
occurring in less than one year after the diagnosis and limited upper motor neuron involvement 45, 
while D90A mutation (the most common SOD1 mutation worldwide and in the sporadic 
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population) correlates with non-penetrant or slowly progressive disease. Remarkably, 2–3% of the 
population, in northern Scandinavia, is heterozygous for the D90A mutation, which is a benign 
polymorphism 46. However, homozygous individuals for D90A in that region develop slowly 
progressive motor neuron disease with prominent corticospinal signs and prolonged survival of 
more than a decade. By contrast, patients who are D90A heterozygotes outside this genetic pool 
develop classic ALS with survival times of 3–5 years 47. 
It is important to note that some SOD1 mutations can remain asymptomatic throughout life, 
suggesting that not all SOD1 mutations cause ALS onset and some are rather polymorphisms. The 
clinical phenotype associated with a certain mutation in the SOD1 gene is obviously not only 
dependent on the mutation itself, but may also be influenced by the genetic background of the 
patient as well as by environmental factors 48. 
Up to date, there is no conclusive explanation about how the SOD1 mutations cause ALS onset. At 
first, it was hypothesized that mutations would impair the enzymatic activity of the SOD1, thus 
resulting in increased cellular levels of reactive oxygen species (ROS), oxidative stress and then 
neuronal death 49. However, results obtained through both in vitro and in vivo experimental 
models has provided numerous evidences that led to abandon this initial hypothesis in favour of a 
new hypothesis that result into the acquisition of a novel toxic function to motor neurons (gain-of 
function hypothesis). In fact, it has been demonstrated that the overexpression of SOD1 WTL-
mutants in cell models induces apoptosis in neurons 50 and that SOD1 knockout mice do not 
develop motor neuron disease 51. 
To date, different hypothesis have been made to explain the SOD1 toxicity. The aggregation 
hypothesis is particularly attractive because protein aggregates are frequently associated with 
neurodegenerative diseases as ALS 5. Numerous studies revealed that SOD1 mutant is incline to 
misfolding and to form cytoplasmic aggregates. In turn, these aggregates could lead to cell death 
by sequestering other cytoplasmic proteins essential for neuronal survival, by clogging the 
ubiquitin/proteasome system, by chaperones depletion, or by disrupting mitochondria, 
cytoskeleton and/or axonal transport 52. Another hypothesis was that the misfolding of SOD1 
induced by mutations would allow the access of abnormal substrates such as peroxynitrite to the 
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1.4 ALS6/Fused in sarcoma/Translocated in liposarcoma (FUS/TLS). 
1.4.1 Structure and functions. 
FUS/TLS (Fused in sarcoma/Translocated in liposarcoma, also called FUS) was originally discovered 
as a result of characteristic chromosomal translocations in myxoid liposarcoma 54. The gene is 
located in chromosome 16 (16p11.2) and consists of 15 exons that encode for a 526 amino acid 
protein, member of the TET family,  a family of proteins implicated in various roles of gene 
expression 55,56. It is characterized by an N-terminal transactivating domain enriched for glutamine, 
glycine, serine, and tyrosine (QGSY region), a glycine-rich region (GRR) followed by a RNA 
recognition motif region (RRM) which contains a nuclear export signal (NES) near its 5′ end, a 
multiple arginine/glycine/glycine (RGG rich) repeats containing a zinc finger (ZnF) domain, and 
finally a nuclear localization signal (NLS)57,58 (Fig. 4). 
 
Figure 4: Genomic and structural organization of human FUS/TLS gene and protein. FUS/TLS gene is encoded by 15 
exons that cover an 11.6 kb region on chromosome 16p11.2. Protein coding exons (filled boxes) and non-coding exons 
(open boxes) are drawn to scale. SYGQ rich: serine–tyrosine–glycine–glutamine rich domain; G rich: glycine rich 





FUS is an ubiquitously expressed and highly conserved multifunctional protein, mostly localized 
into the nucleus and with low levels in the cytoplasm. The precise role of FUS is not fully 
elucidated but it is now known that it is involved in multiple levels of RNA processing including 
transcription, splicing, transport and translation 60. FUS acts also as a transcription regulator. It 
interacts with several gene-specific transcription factors such as NF-B and it is also associated 
with the general transcriptional machinery and may influence transcription initiation and 
promoter selection by interacting with RNA polymerase II and the TFIID complex 61,62. Less is 
known about the role of FUS in splicing regulation. Proteomic analysis identified this protein as 
part of the spliceosome machinery 63. It has been shown that FUS associates in vitro with large 
transcription–splicing complexes that bind the 5’ splice sites of pre-mRNA 64 and has been also 
proposed to directly bind pre-mRNA 3’ splice site 65. FUS seems to play roles in micro-RNA 
processing. It has been found (by mass spectrometry) associated with Drosha, the nuclear RNase 
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III-type protein that mediates the first step in miRNA maturation 66. FUS plays also a cytosolic role 
in regulation of RNA subcellular localization, translation and decay. In particular, FUS was shown to 
relocalize to the cytoplasm upon inhibition of RNA polymerase II transcription 67 and increasing 
evidences suggest that it is integral component of RNA stress granules (SGs), cytoplasmic 
microscopically visible foci consisting of mRNA and RNP complexes that stall translation under 
stress conditions 68. Furthermore, several lines of evidence suggest that FUS is required for the 
maintenance of genomic integrity and may have a role in DNA double-strand break repair. Indeed, 
FUS promotes the annealing of homologous DNA and the formation of DNA D-loops, an essential 
step in DNA repair by homologous recombination 69. 
1.4.2 FUS mutations. 
About 5% of all fALS and 1-2% of sALS cases are due to mutations in the locus ALS6 on 
chromosome 16 that codes for FUS (Fused in Sarcoma, OMIM #608030). After the first report in 
2009 by two independent groups 70,71, a total of 47 mutations have been described in ALS patients, 
among these the majority are missense mutations, but they also include deletions (only R495X), 
truncations and in-frame insertions72. Almost all of the pathological mutations show an autosomal 
dominant inheritance pattern except for one recessive mutation (H517Q) found in a family of Cape 
Verdean origin 70. Most of FUS ALS-linked mutations are clustered at the C-terminal domain of the 
protein and in particular in the Nuclear Localization Signal (all 5 the arginines in this region have 
been identified to be mutated in ALS). The majority of the other ALS associated FUS mutations 
occur in the GRR (Fig.5). The redistribution of the protein from the nucleus to the cytoplasm is 
related to the onset and progression of the disease and mutations that affect amino acid residues 
responsible for the binding to Transportin receptors (thus affecting the nuclear import of the 
protein) result in a more severe disease progression 73. 
The site and age of disease onset are variable within families, and incomplete penetrance has 
been documented for several FUS/TLS mutations, which may account, at least in part, for the 
absence of family history in sporadic patients. Interestingly, several patients harbouring the same 
R521C mutation developed an unusual presentation including an early-onset drop-head syndrome 
74,75. 
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Figure 5: FUS mutations in ALS. Forty-seven mutations have been identified in FUS/TLS in sporadic and familial ALS 
patients. Most mutations are clustered in the last 17 amino acids and in the glycine-rich region and the putative prion 




This is an atypical phenotype, as only 1% of ALS patients present with severe weakness of neck 
extensor muscles in the early stage of the disease course 77. Most patients with FUS develop a 
classical ALS phenotype without cognitive defect. The truncating mutation R495X and the 
missense mutation K510R, discovered in four German ALS families, were associated with an 
aggressive disease course and with a mild phenotype with disease duration ranging from 6 to 8 
years, respectively 78. Analysis of brain and spinal cords from patients with FUS mutations revealed 
normal nuclear levels in the nuclei of many neurons and glial cells, but with FUS cytoplasmic 
aggregations in neurons 71,70. It has not been reported if FUS inclusions are also present in glial 
cells. Cytoplasmic inclusions of FUS protein are absent in controls, in patients with SOD1 mutation 
and in sporadic ALS cases that are presumably positive for TDP-43 aggregations. Importantly, 
TDP43 positive inclusions are absent in FUS mutant patients, implying that neurodegenerative 
processes driven by FUS mutations are independent of TDP-43 aggregation 71. 
1.5 ALS10/Transactive response DNA-binding protein-43 (TARDBP-43/TDP43). 
1.5.1 Structure and functions. 
TAR-DNA binding protein (TARDBP or TDP43) was identified in 1995 as a 43-kDa cellular factor 
binding TAR regulatory sequence of LTR in HIV-1 virus genome. The gene is located on 
chromosome 1 (1p36.22) and consists of 6 exons that encode for a 414 amino acid protein, 
member of the family hnRNPs, RNA binding proteins family 60 containing a nuclear export signal 
(NES) and a nuclear localization signal (NLS), that enable it to shuttle between the nucleus and the 
cytoplasm, potentially to transport bound mRNAs 79, two RNA recognition motifs (RRM1 and 2), 
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able to interacts with RNA and DNA, and a C-terminal glycine-rich region which is able to mediate 
protein–protein interactions 80,81 (Fig. 6). 
 
Figure 6: Schematic diagram of the TARDBP gene and TDP-43 protein. Exon 1 of TARDBP is non-coding and exons 2–6 
are protein coding. TDP-43 contains five known functional domains: nuclear localisation signal (NLS), nuclear export 
signal (NES), two RNA recognition motifs (RRM1 and RRM2) and a glycine-rich C-terminal region. Each RRM has two 




TDP-43 is predominantly localized into the nucleus with low levels in the cytoplasm. TDP-43 is a 
multifunctional protein involved in various steps of RNA processing including transcription, pre-
mRNA splicing, mRNA transport and translation, although the exact cellular functions remain 
elusive 82. TDP43 acts as a transcription factor and has been shown to bind to chromosomally 
integrated TAR DNA to repress transcription of HIV-1 80. It has also been shown to bind to the 
promoter of the mouse SP-10 gene, which is required for spermatogenesis. The C-terminal domain 
of TDP43 is involved with exon skipping and splicing inhibitory activity through the interaction with 
other hnRNP family proteins 60. TDP43 also plays a role in RNA post-transcriptional regulation. 
TDP43 is recruited to stress granules (mRNA and RNP complexes where protein synthesis is 
temporarily arrested), indicating that TDP43 may play a protective role against cellular insult 83. 
TDP43 may play a role in microRNA biogenesis and processing as it has been found to associate 
with Drosha, the RNase III enzyme responsible for initiating the processing of miRNA 60. 
Independent studies using knockout mouse models have shown that TDP43 protein is essential for 
normal prenatal development and viability 84. Knockdown of TDP43 in human cells resulted in cell 
cycle disruption and increased apoptosis, thereby demonstrating a critical role for TDP43 in cell 
survival possibly through maintaining genomic stability 85. TDP43 silencing in human embryonic 
kidney (HEK293) and neuronal (SH-SY5Y) cells has resulted in downregulation of HDAC6, a protein 
necessary for protein aggregate formation and degradation 64. 
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1.5.2 TDP43 mutations. 
In early 2008, the successful identification of dominant mutations as a primary cause of ALS 
provided evidence that aberrant TDP43 can directly trigger neurodegeneration. Up to date, more 
than 40 mutations have been found in the locus ALS10 (OMIM #612069) of ALS patients, 
accounting for about 5 % fALS cases and 2% of sALS 86. Most of the mutations identified are 
localized in the glycine-rich region encoded by exon 6 (Fig. 7). All mutations are dominant 
missense changes with the exception of a truncating mutation at the extreme C-terminal of the 
protein (Y374X) 87. Several variants lying in the non-coding regions of the TARDBP gene have been 
identified in patients but further studies are necessary to prove their pathogenic effect 88,89. 
 
Figure 7: TDP43 mutations in ALS. Forty-four mutations have been identified in TDP43 in sporadic and familial ALS 
patients, with most lying in the C-terminal glycine-rich region. All are missense mutations, except for the truncating 
mutation TDP43
Y374X




Most patients with TDP43 mutation develop a classical ALS phenotype without cognitive deficit, 
with some variability within families in the site and age of onset 90,91. The A382T mutation, first 
identified in two fALS cases from France 92, has the highest prevalence since it was then described 
in 48 fALS families and 47 sALS. Interestingly, the A382T mutation was identified as a founder 
mutation in ALS patients from Sardinia, where 40 fALS and 30 sALS cases shared this mutation. The 
mutational frequency for A382T is about 30% in Sardinia (50%–80% fALS, 9%–23% sALS) 93,94. 
Geographically, most of the mutations identified were in ALS patients from Europe. However, a 
considerable number of ALS patients with TDP43 mutations have been identified in patient 
cohorts from Japan, Australia, North America, and China, suggesting that TDP43 mutations are a 
global cause of ALS 95. 
Postmortem analysis of patients with TDP43 mutations found a pattern similar to the TDP43 
pathology described in sporadic ALS and FTLD patients. TDP43 inclusions are not restricted to 
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motor neurons but can be widespread in brain in ALS patients with or without dementia 96,97. A 
very curious, and mechanistically unexplained, aspect of TDP43 pathology is a significant TDP-3 
nuclear clearance in a proportion of neurons containing cytoplasmic aggregates, suggesting that 
pathogenesis may be driven, at least in part, by loss of one or more nuclear TDP43 functions 98,99. 
Although a plethora of early reports did not establish how prominent this nuclear clearing was and 
whether it escalates in frequency during disease progression, further efforts, especially the work 
of Giordana et al. 97, have established that the cytoplasmic redistribution of TDP43 appears to be 
an early event in ALS. The pre-inclusions and the larger TDP43 inclusions are only partially labelled 
with anti-ubiquitin antibodies 97, whereas intranuclear and cytoplasmic inclusions are strongly 
recognized by phosphorylation-specific antibodies to TDP43 100,101. Interestingly, the composition 
of TDP43 inclusions seems to differ between cortical brain and spinal cord in ALS patients, as 
inclusions from cortical regions are preferentially labelled by C-terminal antibodies, whereas spinal 
cord inclusions display equivalent immunoreactivity between N- and C-terminal-specific antibodies 
99. In accordance with this, spinal cord extracts showed an absence or only weak accumulation of 
25 kDa CTFs compared with brain extracts 101. 
1.6 ALS experimental models. 
In order to better understand the pathophysiological processes of the ALS onset, have been 
created over the years several model systems such as cell lines and transgenic animals, expressing 
different ALS-causative genes (SOD1, FUS and TDP43) in the wild type form or with the several 
pathological mutations. 
1.6.1 Cellular and animal models for SOD1. 
Over time, several cellular models stably or transiently espressing the SOD1 gene linked to ALS 
have been generated. These have helped to elucidate the molecular cascade of events able to 
induce cellular toxicity and the cellular mechanisms of disease 35. 
The first model of motor neuron degeneration SOD1-related was created inhibiting chronically 
SOD1 expression through the use of antisense oligodeoxynucleotides or diethyldithiocarbamate in 
organotypic cultures of spinal cord. This study showed that chronic inhibition of SOD1 was able to 
induce the apoptotic degeneration of spinal neurons, including motor neurons, and that the 
degeneration increased when it was also inhibited glutamate transport 102. The same results were 
obtained in a study conducted on PC12 cells (rat pheochromocytoma cells), where it has been 
observed apoptotic cell death after downregulation of the SOD1 expression 103. Recently it was 
shown that the expression of SOD1-G93A, in co-cultures of human glioblastoma and 
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neuroblastoma cells, induces caspase-1 activation, release of cytokines and activation of apoptotic 
pathways, as also confirmed for other pathological mutants related to fALS (G37R, G85R and 
I113T) 15. 
A limit of transient or stable transfection experiments both in human and mouse cells is the low 
endogenous gene expression level due at the low efficiency of conventional transfection methods. 
In recent studies it was tried to solve this problem by infecting different cellular models with 
replication-deficient recombinant adenoviruses, encoding for wild type SOD1 or with pathological 
mutations, to obtain similar expression levels both exogenous and endogenous SOD1 proteins. In 
an in vitro cell culture system, it has been revealed that infection of mouse NSC-34 motor neuron-
like cells with adenovirus encoding for mutant SOD1-G93A gene increased cellular oxidative stress, 
mitochondrial dysfunction, cytochrome c release and motor neuron cell death 104. 
The animal models if compared to cellular models allow to more closely mimic the human disease 
and to follow the trend of disease in order to develop effective therapies. Up to date, several 
transgenic mouse and rat strains were created by the introduction of the sequence coding for 
human SOD1 under the control of a promoter that enables ubiquitous expression of the 
transgene. Unlike SOD1 knockouts, transgenic mice and rats with human fALS–SOD1 added to 
their own enzyme exhibit the ALS-like clinical features: hind limb weakness and muscle tremor 
followed by more severe manifestations such as progressive motor paralysis, inability to walk, 
drink and eat, and death within some week. Differences in the age of disease onset among these 
strains seem to depend primarily on the transgene copy number, mice with high transgene copy 
numbers are affected by early onset, while mice carrying small transgene copy numbers are 
affected by late-onset, slowly progressive disease 105,106. Moreover, several biochemical alterations 
observed in patients are, in most cases, preserved in these models such as the appearance of 
oxidative-stress markers, alterations of mitochondria in motor neurons and muscle and the 
activation of phosphorylation cascades 107. Several transgenic lines have been developed, carrying 
mutations at different positions in SOD1. There are, however, some differences between the 
various mutant SOD1 mouse strains depending especially on the mutation and copy number of the 
transgene 37. For example, the progression of the disease is much more rapid in transgenic mice 
for the G86R mutation of the mouse SOD1 (three days) or for the human G85R mutation (7–14 
days) than in mice that are transgenic for human SOD1-G93A (60-110 days) 106. 
Transgenic mice carrying 20 copies of SOD1 with the G93A mutation are the most extensively 
studied. The progression of symptoms in these mice is preceded and paralleled by a sequence of 
structural and functional alterations of motor neurons. As for other diseases, the great advantage 
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of animal models that mimics human pathology is the possibility to follow the stepwise 
progression of the disease for the design of potential therapeutic strategies. However, the 
expression levels of mutant SOD1, in heterozygous ALS patients, needed to exert its toxic effects is 
much lower than for transgenic rodents. In fact, in these models is necessary an increase about 10-
30 fold of mutant protein level to induce the pathological phenotype. This is due to differences 
between mice and man and it should not be overlooked when using mice models 5. 
1.6.2 Cellular and animal models for FUS. 
To date, the role of FUS in ALS pathogenesis has not been established. It has been suggested that 
the toxicity of FUS could be the result of a gain-of-function for this protein, instead if mutated is 
possible a loss of function probably through its sequestration in stress granules. The generation of 
cellular and animal models of FUS could be provide several key insights into understanding the 
molecular mechanisms that might contribute to ALS pathogenesis. 
Due to ALS-linked mutations, FUS becomes redistributed to the cytoplasm, a consistent 
observation well documented in human FUS-related ALS patients 70,71. These observations suggest 
that the cytoplasmic localization of mutant FUS might be a pre-requisite for causing toxicity. In 
several cell culture experiments have been analyzed the effects on subcellular localization of FUS 
carrying different C-terminal NLS mutations. Strong cytoplasmic localization was seen in 
transfected murine N2a cells when a consensus nucleotide of the NLS was mutated (the strongest 
effect corresponded to human FUS amino acids K510, R522 and P525). Mutations in the NLS that 
are not part of the consensus sequence gave weaker cytoplasmic localization 108. Studies on stable 
HEK-293 cell lines that express GFP-tagged FUS constructs, including wild type FUS or mutants, 
revealed a mutant-specific response to cellular stress that leads to the incorporation of 
cytoplasmic fALS-linked FUS protein into stress granules. The same results have been confirmed 
injecting mRNAs encoding GFP-FUS (WT or mutants) in zebrafish eggs at the 1–2 cell stage 109. 
Several groups have generated a yeast model of FUS-related neurodegeneration by expressing WT 
and disease associated FUS. Yeast cells expressing the C-terminal fragment with the zinc finger and 
GRR domain of FUS with ALS-associated mutations causes cytotoxicity under certain conditions 110. 
Another study has demonstrated that FUS localized to the cytoplasm and nucleus when expressed 
starting from a weak promoter, suggesting that the FUS expression level is an important 
determinant of localization and aggregation of FUS in yeast cells. It is possible that the non-
canonical NLS of FUS might not be functional in yeast cells or that predominant nuclear 
localization of FUS requires additional factors such as post translational modifications 110,111. 
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Drosophila models of FUS related neurodegeneration were recently generated that recapitulate 
several features of the human disease 112,113. In one study, ectopic expression of FUS with ALS 
linked mutations in the fly eyes caused moderate to severe external eye degeneration when 
compared to ectopic expression of FUS WT. Interestingly, targeted expression of FUS in the fly 
brain and motor neurons led to the pupal lethality and larval locomotor defects. Conditional 
expression of mutant FUS in neurons drastically reduced the life span and adult climbing abilities 
as compared to FUS WT expressing animals 114. Recently, it has been demonstrated that knocking 
down endogenous FUS in zebrafish leads to defects such as motor neuron degeneration, 
hyperbranched axons from motor neurons and behavioural phenotypes such as a defect in touch-
evoked escape response, suggesting that loss of FUS function can lead to neurodegeneration 115. 
These observations are further supported by another study where knocking out endogenous 
cabeza (the fly homologue of human FUS) can cause motoneurons degeneration in Drosophila 113. 
Interestingly, the motor phenotypes caused by zebrafish FUS knockdown can be rescued by 
expressing human FUS WT, suggesting that human and zebrafish FUS are functionally related 
proteins. Furthermore, the expression of the ALS-linked mutation R521H also leads to motor 
neuron phenotypes, indicating that FUS with disease-causing mutations acquires a toxic gain of 
function. Two independent groups have generated FUS knock out (KO) mouse models long before 
the identification of ALS-linked mutations in FUS. The FUS KO mice were smaller in size as 
compared to non-transgenic animals, they have shown a chromosomal abnormalities indicating 
that FUS plays an important role in the stability of the genome and a complete male sterility and 
reduced fertility in females indicating that FUS is required for normal development and fertility.  
Many of them died within 16 h of birth, suggesting that normal levels of FUS are required for 
viability of neonatal animals 116,117. Studies on rat models have demonstrated that overexpression 
of FUS WT was enough to cause neurodegeneration at an advanced age with a moderate but 
significant loss of neurons in the brain. However, expression of mutant FUS led to severe 
neurodegeneration at an early age as compared to FUS WT expressing rats 118. Moreover, only rats 
espressing mutant FUS have shown paralysis and accumulation of ubiquitinated proteins in the 
cortex and spinal cord. Interestingly, the ubiquitinated inclusions were only present in the FUS 
expressing cells, but there was no colocalization between FUS and ubiquitinated inclusions. The 
ubiquitinated inclusions have showed reactivity with a mitochondrial marker protein in this rat 
models of mutant FUS, suggesting that damaged mitochondria might be ubiquitinated and 
subsequently degraded 118. 
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1.6.3 Cellular and animal models for TDP43. 
More and more groups are engaging in research that examines the role of TDP43 in the 
pathogenesis of ALS. An increasing number of disease cellular or animal models have been set up 
to provide insights into the molecular mechanism of ALS with TDP43 proteinopathy. Nonetheless, 
the exact role of TDP43 in the pathogenesis of FLTD/ALS still has not been fully unravelled and 
probably both a gain of toxic properties and a loss of function via its sequestration in aggregates 
could be possible. 
In several cell culture experiments, the expression of TDP43 proteins carrying mutations that 
disrupt its NLS led to localization primarily within the cytoplasm 119. A study on rat primary cortical 
neurons, through an automated microscopy system for long-term visualization, has shown that 
overexpression of wild-type TDP43 led to increased cytoplasmic localization of TD-43 and cell 
death independently of mutation, pathogenic TDP43 mutations increased the proportion of 
cytoplasmic TDP43 120. As reported in different studies the overexpression of WT or mutant 
hTDP43 in transgenic mice induced motor dysfunction, such as gait disorders. In particular, it has 
been shown that moderate expression of hTDP43 (about 2.5 fold) can promote cytoplasmic TDP43 
expression, TDP43 truncation, TDP43 phosphorylation and TDP43 aggregation, which mimics the 
TDP43 proteinopathy in CNS of ALS. Besides TDP43 proteinopathy, abnormal mitochondrial 
aggregation is observed in hTDP-43-overexpressing transgenic mice, indicating the involvement of 
TDP43 in mitochondrial trafficking 121,122. The overexpression of WT-hTDP43 or mutant hTDP43 in 
rat models increases cytoplasmic TDP43 expression. However, only rats expressing mutant hTDP43 
(M337V-hTDP43) exhibited significant motor dysfunction, which is different from other mouse 
models. M337V-hTDP43 expression in rat also reproduces the biochemical features of ALS 
including hyper phosphorylation of TDP43, formation of TDP43 inclusion and expression of 
truncated TDP43. Most importantly, the ubiquitous expression of M337V-hTDP43 in rat is seen to 
cause more severe neurodegeneration in the motor system than in the CNS 123. Similar results 
were also obtained  non-human primate models 124 and on non-mammalian transgenic animal 
models as C. elegans 125, Zebrafish 126 and Drosophila 127. 
Fragments (20–25 kDa) containing the carboxy-proximal portion of TDP43 accumulate in detergent 
(sarkosyl)-insoluble fractions derived from patient CNS tissues. The truncated TDP43 (~25 KDa) has 
been involved in disease progression by gain of toxic function 98. When expressed in cells, the 25 
kDa CTFs recapitulate some of the pathological features such as increased cytoplasmic 
accumulation, insolubility, hyperphosphorylation, polyubiquitination and cytotoxicity 99,128. 
Transgenic mice expressing the 25 kDa C-terminal fragment of TDP43 develop cognitive deficits 
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without cytoplasmic TDP43 inclusions and trigger the processing of endogenous TDP43, which 
suggest that TDP43 inclusions are independent of cognitive dysfunction 129,130. Caspase-3, which is 
activated during apoptosis, has been proposed to be the main protease generating the 25 kDa CTF 
in cells 128,131. The role of TDP43 ubiquitination in disease pathogenesis remains unknown, 
although it is likely to be a late event, since in patients the pre-inclusions and most TDP43 
inclusions are either weakly or not at all ubiquitinated 97,100. Nevertheless, extensive ubiquitination 
of the pathologic CTFs in cells 132 suggests that cellular degradation machineries such as the 
ubiquitin-proteasome system (UPS) and/or autophagy 133 may be involved in removing TDP43 
aggregates. 
To investigate the linkage between the loss-of-function of TDP43 and pathological features ALS, 
TDP43 knockout models have been created. TDP43 is important for early embryonic development, 
in fact TDP43 knockout in mice would result in peri-implantation lethality 84. Targeted depletion of 
TDP43 in motor neurons could trigger mice with age-dependent progressive motor neuron 
degeneration, muscle atrophy and motor dysfunction, which are reminiscent of human ALS 
patients. These findings indicated that TDP43 might be important for the long-term maintenance 
of motor neuron 134 135. Therefore, the mouse model with depletion of TDP43 expression in motor 
neuron not only has a longer lifespan compared to the whole body knockout, but also could be a 
valuable model for studying the role of TDP43 in motor neurons 136. 
Further studies on the molecular mechanism of ALS with TDP43 proteinopathy are needed. 
1.7 Physiopathological mechanisms of ALS. 
Current hypotheses on biology underlying both sporadic and familiar ALS forms in humans outline 
a complex model in which non-competing mechanisms including not only gene mutations and 
environmental factors but also oxidative stress, protein aggregation, excitotoxicity, changes in the 
ubiquitin-proteasome system and autophagy pathways, defects in RNA metabolism, abnormal 
axonal transport, as well as neuroinflammatory processes involving astrocytes and microglia, are 
likely to converge in various unfortunate patterns to mediate selective motor neuron 
degeneration (Fig. 8). 
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Figure 8: Proposed mechanisms underlying neurodegeneration in ALS. Many of these pathways are mechanisms of cell 
death common to a range of neurological disorders, although in the case of amyotrophic lateral sclerosis (ALS), have 
been derived from studies undertaken predominantly using the SOD1 mouse model. Pathophysiological mechanisms 
involving more recent genetic discoveries, particularly the C9orf72 hexanucleotide repeat expansion, have yet to be 
elucidated. Neurodegeneration in ALS might reflect combinations of glutamate excitoxicity, generation of free 
radicals, mutant SOD1 enzymes, along with mitochondrial dysfunction and disruption of axonal transport processes 
through accumulation of neurofilament intracellular aggregates. Mutations in several ALS-related genes are 
associated with the formation of intracellular aggregates, which appear harmful to neurons. Activation of microglia 
results in secretion of proinflammatory cytokines resulting in further toxicity. Failure of cytoplasmic mitochondria 
induces increased susceptibility to glutamate-mediated excitotoxicity, perturbations in motor neuronal energy 
production, and apoptosis. Mitochondrial dysfunction is associated with increased production of reactive oxygen 
species (ROS). Cytoplasmic aggregates of SOD1 might directly inhibit conductance of VDAC1, thereby reducing the 
supply of ADP to mitochondria for ATP generation. Δ ψ =mitochondrial membrane potential 39. 
1.7.1 Oxidative Stress. 
Oxidative stress arises when the levels of ROS/RNS exceed the quantities required for normal 
redox signalling. There has been particular interest in the role of oxidative stress in ALS but the 
exact role of ROS/RNS in disease processes is uncertain 137. ROS are able to cause permanent 
oxidative damage to several cellular components such as proteins, DNA, lipids, and cell 
membranes 138. They has been detected in the spinal cord and cerebrospinal fluid (CSF) of sALS 
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patients 139. SOD1 and its antioxidant properties have been studied extensively from the 
perspective of redox regulation in ALS 140. The first hypothesis proposes that mutations in SOD1 
alter its ability to act as an antioxidant but further evidences showed that disease onset is not 
associated with its enzymatic activity 141. However, mutant SOD1 could accept peroxynitrite or 
hydrogen peroxide as a substrate, and thereby catalyse the nitration of tyrosine residues of SOD1 
and hydroxyradicals 53,142, in fact high levels of nitrotyrosine and nitrated proteins have been 
found in the CSF of both sALS and fALS patients 139.The second hypothesis suggests that mutant 
SOD1 fails to bind zinc correctly, allowing the rapid reduction of the SOD1-bound copper which 
catalyses the formation of superoxide anion rather than dismutation 143. 
Mutant TDP-43 may be itself an inducer of oxidative stress, as suggested by studies in neuronal 
cells in vitro in which this protein was shown to down regulate heme oxygenase-1 144 and in yeast, 
in which TDP-43 expression increased markers of oxidative stress and induced cell death 145. 
1.7.2 Glutamate Excitotoxicity. 
Another component of neuronal degeneration in many neurodegenerative disorders is excessive 
glutamate-induced stimulation of postsynaptic glutamate receptors resulting in increased calcium 
intake and neuronal injury 146. Glutamate uptake from most synapses in the CNS is controlled by 
excitatory amino acid transporter 2 (EAAC2; also known as SLC1A2 or GLT1) 147. Increased levels of 
intracellular glutamate and decreased uptake of glutamate from the synapse have been observed 
in ALS patients 148. Indeed, in most cases of sALS, and in transgenic rodent ALS models, there is a 
profound reduction in the expression and activity of EAAT2 in the cortex and spinal cord 149. 
Excitotoxicity has provided one of the few examples of a mechanistic link between mutant SOD1 
mediated the sporadic form of the disease. The presence of mutant SOD1 increases the sensitivity 
of motor neurons to glutamate toxicity 150, causes alteration in AMPA receptor subunit expression 
151, and causes reduced expression of the major glutamate reuptake transporter EAAT2 107. 
Whether as a primary or a propagating process, it appears that glutamate toxicity plays a 
contributory role to the injury of motor neurons in ALS. 
1.7.3 Mitochondrial Dysfunction. 
Numerous studies have focused on the role of the mitochondrion in the pathogenesis of 
neurodegenerative diseases like ALS. Indeed, mitochondrial alterations are observed in the spinal 
cord cells of SALS patients and role of mitochondria has been well studied in relation to ALS 
pathogenesis 152. It has been demonstrated presence of abnormal and degenerate mitochondria 
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either in ALS patients 153 as well as in cellular and animal models of disease 154,155, although how is 
unclear relationship between non-functioning mitochondria and ALS onset. 
In particular, expression of mutant SOD1 in motor neuron cell line (NSC34) results in the 
development of swollen mitochondria, impaired activity of complexes II and IV of the 
mitochondrial respiratory chain, impaired cellular bioenergetic status, and alteration in the 
mitochondrial proteome 156. Similarly, G93A-SOD1 mice show reduced respiratory chain activity 
and reduced ATP synthesis 157. Furthermore, recent studies have shown that overexpression of 
TDP-43 causes mitochondrial dysfunction and induces mitophagy in cell culture 158.The presence of 
ROS and impairment of the mitochondrial respiratory chain have also been observed in TDP-43 
models 144. 
Significantly, any pathological variations in regulation of the electron transport chain would result 
in more oxidative stress 159 causing further cellular redox dysregulation, leading to a potential 
vicious cycle of damage and degeneration. 
1.7.4 Impaired Axonal Transport. 
Axonal transport is a key mechanism required for cellular viability in neuronal cells. The transport 
of molecules and organelles is a fundamental cellular process that is particularly important for the 
development, function and survival of neurons. Several findings indicate that dysfunction of 
axonal transport might contribute to the demise of motor neurons in ALS 155. Firstly, 
neurofilaments (NF) accumulation in motor neurons is another histopathological hallmark of ALS 
160 and transgenic mice that overexpress NF subunits in motor neurons develop a motor neuron 
disease with impaired axonal flow, as axonal defects cause delay in transportation of components 
required for the maintenance of axon 155. Second, both slow and fast anterograde transport are 
slowed in transgenic G93A-SOD1 and G37R ALS mice prior to disease onset and these deficits are 
exacerbated. as the disease progresses 161. Tird, retrograde transport is also disrupted in ALS mice 
162. A recent study demonstrated that oxidised wild-type SOD1 immunopurified from sALS patient 
tissues inhibited kinesin-based axonal transport in a manner similar to mutant SOD1 in fALS 
providing evidence for common pathogenic mechanisms in both sALS and fALS 163. It has been  
showed that NF aggregations are associated with SOD1 and nitric oxide synthase activities leading 
to nitrotyrosine formation on NF 164. Nitrotyrosine can inhibit phosphorylation of NF subunits and 
may alter axonal transport and initiate motor neuron death 164. Taken together, these findings 
suggest a relation between redox regulation and axonal transport dysfunctions in ALS. 
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1.7.5 Inflammatory cascades and the role of non-neuronal cells. 
Recently there has been increasing interest in the possibility that non-neuronal cells, including 
activated microglia and astrocytes, may contribute to the pathogenesis or propagation of the 
disease process in ALS. Several studies on mouse models have indicated that expression of mutant 
SOD1 in neurons alone is insufficient to cause motor neuron degeneration and that participation 
of non-neuronal cells may be required 15. 
Astrocytes have many functions relevant to motor neuron physiology. First, they express the most 
important glutamate transporter EAAT2/GLT-1, thus contributing to the clearance of this 
neurotransmitter; deficiency of astroglial EAAT2/GLT-1 causes severe motor neuron loss 165 and 
alteration of this transporter has been repeatedly invoked as a cause contributing to ALS 9. 
Second, astrocytes are the major source of both trophic 166 and toxic factors 15 for motor neurons. 
Several cytokines have been proposed to play a role in ALS as reinforcing signals from glia cells, 
including interleukin-6 (IL6), tumour necrosis factor α (TNFα) and transforming growth factor β1 
(TGFβ1) that were found increased in cerebrospinal fluid, plasma and epidermis from ALS patients, 
although with sometimes conflicting results 167. In addition, the production of nitric oxide and the 
activation of cyclooxygenase type 2 (COX2) aggravate the toxic effects of mutant SOD1 in several 
experimental models for ALS. The production of all those proinflammatory mediators may be 
secondary to the induction of the transcription factor NF-κB, which is activated in the presence of 
reactive oxygen species (ROS) and by many other different signalling molecules associated with 
ALS onset and progression 168. NF-κB activation has been observed in astrocytes from ALS patients 
and in human cells expressing mutant SOD1 169. NF-κB also regulates the expression of COX2 that 
may cause an increase in the synthesis of prostaglandins, which trigger astrocytic glutamate 
release and induce free radical formation, thus contributing to both excitotoxicity and oxidative 
damage. Indeed, treatment with COX2 inhibitors markedly protects motor neurones and 
significantly prolongs survival of ALS mice 170. Surprising NF-κB downregulation in astrocytes, via 
expression of the dominant negative IκB-alpha-AA, fails to influence onset, severity, or progression 
of disease in a mutant SOD1-based ALS mice model 171. 
Recently it has been shown that also microglia play a critical role as resident immunocompetent 
and phagocytic cells within the CNS. Activation is associated with transformation to phagocytic 
cells capable of releasing potentially cytotoxic molecules including reactive oxygen species, nitric 
oxide, proteases, and proinflammatory cytokines such as interleukin-1B, tumour necrosis factor a 
(TNFα), and interleukin 6 (IL-6) 172. Given this, there is little doubt that activated microglia can 
inflict significant damage on neurons, but their role is complex and they are capable of stimulating 
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neuroprotective as well as neurotoxic effects. Proliferation of activated microglia is a prominent 
histological feature in the spinal ventral horn both in mutant SOD1 transgenic mice and in human 
ALS 173. In the mice, microglial activation is present before the onset of significant motor neuron 
loss or motor weakness. Various inflammatory cytokines or enzymes are upregulated in the spinal 
cord of ALS patients (IL-6, IL-1β, cyclo-oxygenase 2 (COX2), and prostaglandin E2 (PGE2)) or, in the 
spinal cord of mutant SOD1 mice (IL-1β, TNFα, COX2, PGE2) 174. Microglia appear to mediate the 
toxicity to neurons in patients with ALS by releasing factors that enhance glutamate toxicity 175. In 
a recent study D’Ambrosi and colleagues have investigated about how mutant SOD1 affects P2 
receptor-mediated proinflammatory microglial activation, considering that extracellular ATP is one 
of the most widespread microglia alarm signal endogenous to the CNS, and that ATP signaling 
evokes many proinflammatory functions of microglia. They observed up-regulation of P2X(4), 
P2X(7), and P2Y(6) receptors and down-regulation of ATP-hydrolysing activities in mutant SOD1 
microglia. This potentiation of the purinergic machinery reflected into enhanced sensitivity mainly 
to 2'-3'-O-(benzoyl-benzoyl) ATP, a P2X(7) receptor preferential agonist, and translated into 
deeper morphological changes, enhancement of TNF-α and cyclooxygenase-2 content, and finally 
into toxic effects exerted on neuronal cell lines by microglia expressing mutant SOD1 176. The 
purinergic activation of microglia may thus constitute a new route involved in the progression of 
ALS to be exploited to potentially halt the disease. 
1.7.6 Protein aggregation. 
Protein aggregates are often found in spinal motor neurons of all types of ALS patients. These 
inclusions contain many different proteins, some of which may have an intrinsic tendency to 
aggregate following mutation (such as SOD1, TDP-43 and FUS) while others may be simply 
entrapped in aggregates 177. Now, there is hardly a general consensus on the assumption that the 
toxic function gained by SOD1 mutants is related by their tendency to aggregate and to 
mislocalize, as other ALS mutant proteins. This hypothesis is supported by the presence of 
intracellular cytoplasmic (but also mitochondrial) inclusions enriched in SOD1 protein in cellular 
models and in spinal cord motor neurons in animals as well as in motoneurons of ALS patients 
177,178. Over the years, several experimental evidences have been proposed to explain how 
aggregation of mutant SOD1 could be a major contributor to induce cellular toxicity in ALS 
patients, from the ability to sequester proteins required for normal motor neuron function 179, to 
the capacity to reduce proteasome activity needed for normal protein turnover and to inhibit 
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specific organelles function (as the mitochondria) by aggregation out or within the same 
organelles 156,180. 
The fact that protein aggregation is a common theme in ALS and that the cellular degeneration in 
ALS depends upon the sensitiveness of motor neurons to protein aggregation is suggested also by 
the observation that, likewise to SOD1, also TDP43, FUS aggregate in tissues from ALS patients and 
models 181. Anatomo-pathological observations of ALS-affected tissues showed that these two 
proteins abnormally aggregate as cytoplasmic inclusions (positive for ubiquitin, but negative for 
SOD1) and that ALS-related mutations seem to enhance the rate of aggregation 111,182. Recently, it 
has been identified  that aggregation of FUS and TDP43 relies on prion-like domains and that 
aggregated FUS or TDP43 can sequester native protein 183. 
The formation of such intracellular aggregates may depend on the accumulation of misfolded 
proteins generated either as a direct consequence of mutation, or as a consequence of oxidative 
stress. In both instances, impairment of the ubiquitin-proteasome response (UPR) seems to play a 
major role. Not only ubiquitin-immunoreactive inclusions are the most frequently reported 
inclusions in all forms of ALS, but aggregates may be also reactive to p62, a protein which has a 
part in the formation of the sequestosome and in autophagy 184. 
1.7.7 Misregulation in RNA processing. 
Two of the lately identified genetic factors in ALS, TDP43 and FUS, encode for proteins with an 
established role in RNA metabolism. Thus, RNA dismetabolism seems to be an important potential 
physiopathological mechanism in motoneurons degeneration. Since RNA metabolism involves 
several processes, such as pre-mRNA splicing, mRNA transport, translational regulation, or mRNA 
decay, the precise RNA pathway that is affected in ALS disease is still unclear, and it is not 
completely clear whether defects in RNA processing have a causative, direct role in the 
pathogenesis 3. 
Under stress, a cell’s top priority is to conserve energy and divert cellular resources toward 
survival and eventual recovery. In eukaryotic cells, a powerful way to conserve resources is rapidly 
assembly of non-translating mRNAs and their associated RNA-binding proteins into aggregate-like 
structures called RNP granules, including stress granules (SGs) 185. In normal cells, TDP43 and FUS 
are nuclear proteins that can quickly be shuttled to the cytoplasm upon stress induction where 
they can rapidly associated with SGs 73,186. Once the instigating stress resolves, SGs dissolve and 
TDP43 and FUS return to the nucleus. Thus, the nuclear-cytoplasmic shuttling of TDP43 and FUS, 
as well as their association with cytoplasmic SGs, are physiological and reversible processes. 
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However, in pathological conditions, the nuclear-cytoplasmic shuttling of TDP43 and FUS becomes 
dysregulated, possibly However, in pathological conditions, the nuclear-cytoplasmic shuttling of 
TDP43 and FUS becomes dysregulated, possibly owing to diverse genetic and environmental 
factors, or perhaps even aging itself 187. Several models have been proposed to explain the role of 
FUS, TDP43, and SG biology in ALS pathogenesis: i) The gain-of-function (GOF) toxicity model 
asserts that pathological TDP43 or FUS aggregate in SGs, impeding normal SG-mediated RNA 
homeostasis. In this model, the excessive SG localization of FUS and TDP43 109,188 might drive 
dysregulated assembly of inappropriate fibrillar aggregates 111, which perturb the localization of 
messenger RNPs (mRNPs) required for RNA processing and decay, thereby interfering with RNA 
sorting. If this process continues unabated, ultimately the assembly of translation initiation 
complexes could be affected by preventing the increase in local concentration of mRNAs and 
translation factors 189. Finally, insoluble FUS and TDP43 aggregates alter SG dynamics even after 
stress resolution 190, resulting in SG persistence as has been observed in cells expressing ALS-
associated TDP43 or FUS mutants 109,188; ii) The cytoplasmic loss of function (LOF) model suggests 
that FUS and TDP43 are critical mediators of nuclear-cytoplasmic RNA transport and shuttling, 
which affect the physiology of SG formation during stressful conditions. TDP43 has been 
repeatedly demonstrated to have pronounced effects on SG dynamics, as delayed formation, 
reduced size, altered morphology, and limited stability of SGs are observed in HeLa cells and 
neuroblastoma cell lines depleted of TDP43 191. In addition, WT FUS appears to be recruited to 
dendrites by mGluR5 activation in neurons, where it mediates a rise in local RNA content, and FUS-
null neurons demonstrate abnormal spine morphology and density 192, underscoring that loss of 
normal FUS function can contribute to pathogenesis; iii) Although the cytoplasmic LOF model is 
consistent with many aspects of TDP43 and FUS pathological interactions, both proteins have well 
established important nuclear roles as well, including premRNA splicing, RNA stability, and 
transcriptional regulation 60. Thus, depletion of nuclear pools of TDP43 and FUS is likely to impact 
these essential functions. Moreover, ALS-linked mutations might even subtly impair nuclear TDP43 
or FUS function in a manner that is selectively toxic for motor neurons upon aging and may not 
even require depletion of nuclear pools 193,194. 
1.7.8 Autophagy dysfunction. 
It is known that autophagy is essential to neuronal homeostasis, and may in some settings be 
neuroprotective 133. Mice with conditional knockout of Atg genes die prematurely with extensive 
neurodegeneration and ubiquitin-positive pathology, which illustrate the importance of autophagy 
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in neurodegeneration 195. However, when autophagy is excessively induced or defective, it can 
result in autophagic cell death (type II cell death), which is defined by the massive accumulation of 
autophagosomes without nuclear condensation 196. Growing evidence supports a role of 
autophagic dysfunction as a contributing factor in various neurodegenerative diseases associated 
with abnormal aggregation of disease-related mutant proteins 197. Several important proteins 
including SOD1 and TDP43 have been identified within inclusions in both sporadic and familial ALS 
47,98. Studies report the altered autophagy in G93A mice that starts from the pre-symptomatic 
stage of the disease 198. The number of LC3-labeled autophagic vacuoles is significant increased in 
the motor neurons of the spinal cords of G93A mice compared with the age-matched controls 
198.However, it is not known whether the increased autophagic vacuoles in motor neurons are the 
result of autophagy induction or autophagy flux impairment. Furthermore, while autophagosomes 
are frequently observed in dying neurons, it is unclear whether autophagy actively participates in 
the process of motor neuron death in ALS. Accumulating evidence suggests that defects in 
autophagic flux or in specific autophagy-regulatory processes, rather than simply induction, may 
contribute to the motor neuron degeneration 199. A recent report indicates that treatment of 
G93A mice with rapamycin significantly inactivates the mTOR signaling pathway, causes further 
accumulation of autophagic vacuoles, but fails to reduce the level of mutant SOD1 aggregates in 
the spinal cord of transgenic G93A mice 200. This study indicates the possibility of abnormal 
autophagic flux in ALS. Recent studies show that inhibition of either the UPS or autophagy 
dramatically increases TDP43 aggregation, suggesting that TDP43 can be degraded by both 
degradative systems 201. Autophagy induction by rapamycin is associated with reduced 
cytoplasmic TDP43 accumulation in neuronal cell lines 202. In addition, an autophagy enhancer, 
trehalose, can reduce TDP43 aggregates by an mTOR-independent pathway way 203. TDP43 
aggregates co-localize with the marker of autophagy LC3 and the adaptor protein p62 201,204. Over-
expression of p62 reduces TDP43 aggregation in an autophagy and proteasome-dependent 
manner 204. A recent report demonstrates that mice overexpressing mutant TDP43 develop a 
progressive and fatal neurodegenerative disease reminiscent of ALS 205. In this mice model, 
aggregates of ubiquitinated proteins selectively accumulated in spinal motor neurons and frontal 
cortex neurons 205(66). Because the ubiquitinated proteins are the substrates for both UPS and 
autophagy pathways, it is likely that mutant TDP43 may impair protein clearance pathways in 
motor neurons. 
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1.7.9 Apoptotic pathways. 
The apoptotic pathways  play an essential part in several biologic events, including 
morphogenesis, cell turnover, removal of harmful cells, and balanced apoptosis is crucial to 
ensuring good health. There are two pathways of activation: i) intrinsic or death receptor pathway, 
cell death are initiated by the binding of a specific protein ligand to a cell surface transmembrane 
receptor; ii) extrinsic pathway or mitochondrial pathway, cell death are activated by perturbance 
of the mitochondria 206. Both pathways induce activation of a series of proteases called caspases. 
Caspase 3 is the effector to both pathways and it is activated by caspase-8 in receptor pathway 
and by caspase-9 in mitochondrial pathway. 
In mitochondrial pathway, caspase activation is mediated by an ATP-dependent multiprotein 
complex called apoptosome, which requires following release of cytochrome-c from mitochondria. 
In fact, Bcl-2 proteins family, located in the outer mitochondrial membrane, are important actors 
to prevent or permit apoptosis and to control release of cytochrome c 207. The relative 
concentration of family members acts as a gauge for cell death. In fact, this family comprises 
antiapoptotic members (Bcl-2, Bcl-xL, Bcl-w, Bfl-1, and Mcl-1) that promote cell survival, and 
proapoptotic members (Bax and Bak) that act as death effectors 206. The balance between pro- 
and antiapoptotic proteins (Bcl-2 family members) expressed in the outer mitochondrial 
membrane probably determines whether programmed cell death is initiated or whether the cell 
will survive 208. 
Involvement of mitochondrial apoptotic pathway in ALS is reinforced by an extensive literature 
that has documented a plethora of apoptotic phenotypes in tissues from patients and transgenic 
mice, as well as in cultured cells overexpressing mutant SOD1s 177. 
Alteration in the expression of the pro- and anti-apoptotic genes, activation of caspases and 
release of cytochrome-c have been found in the spinal cord of transgenic mice expressing SOD1 
with the G93A mutation and in human ALS patients without SOD1 mutations 209,210. It has 
demonstrated that overexpression of SOD1G93A requires the expression of Apaf1 to induce cell 
death 211 and that both WT and mutant SOD1 can bind Bcl2, providing evidence of a direct link 
between SOD1 and an apoptotic pathway 179. Recent papers have investigated expression of the 
Bcl2 family members in spinal cords of transgenic SOD1G93A, SOD1WT and non-transgenic mice 
and it is resulted that Bcl2-A1 is the only member of this family to be upregulated in both 
asymptomatic and symptomatic G93A mice, through NF-kB-independent pathway, with a 
tendency to decrease in the final stages of disease. Interestingly, this upregulation is tissue 
specific, as Bcl2-A1 mRNA is increased neither in the brain nor in the muscle of G93A transgenic 
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mice. Moreover, induction of Bcl2-A1 in SOD1G93A transgenic mice occurs via NF-kB-independent 
pathway 212. Moreover, it has been demonstrated in different cell cultures  (NSC-34, 
undifferentiated and differentiated ETNA cells and primary cultures from spinal cords) that 
overexpression of Bcl2-A1 and SOD1G93A increases the level of cell death after exposure to TNF-
α, a situation which mimics the condition of neuroinflammation occurring in ALS 212. Furthermore, 
it has been reported in immortalized motor neurons (NSC-34) and transgenic mice expressing 
mutant SOD1, that up-regulation of Bcl2-A1 by mutant SOD1 is mediated by activation of the 
redox sensitive transcription factor AP1 and that Bcl2-A1 interacts with pro-caspase-3 via its C-
terminal helix α9. Moreover, Bcl2-A1 inhibits pro-caspase-3 activation in immortalized motor 
neurons expressing mutant SOD1 and thus induction of Bcl2-A1 in ALS mice represents a pro-
survival strategy aimed at counteracting the toxic effects of mutant SOD1 213. 
These observations, together with recent evidence on TDP43 models that has linked its 
overexpression with an increase cell death through up-regulation of Bim expression and down-
regulation of Bcl-xL expression TDP43 models 214, argue for a primary role of mitochondrial 
apoptosis in ALS and suggest that other relevant pathways regulating mitochondrial apoptosis 
needs to be investigated to fully clarify this topic. 
1.8 ALS therapeutic approaches. 
Up to date, the development of effective therapeutic approaches for ALS has been disappointing. 
Riluzole is the only approved treatment, it is a neuroprotective drug that blocks glutamatergic 
neurotransmission in the CNS but it showed limited therapeutic benefits with minimal effects on 
survival and no effect on muscle strength, quality of life or functional capacity, it prolongs life by 
only 2 to 3 months 215,216. In recent years, several studies have enabled to better understand the 
molecular mechanisms underlying the neurodegenerative process and thus to identify new 
therapeutic targets and new therapeutic areas 217, among these we can mention: 
- Stem-cell technologies represent a promising approach for treating ALS. Their developmental 
plasticity, i.e. the ability of stem cells to change their fate in response to extracellular signals, 
stimulated the performance of stem-cell trials in patients. It has been reported that 
transplantation of autologous mesenchymal stem cells into the spinal cord of ALS patients is 
safe and well tolerated 218. However, preliminary stem-cell transplantation trials performed in 
ALS patients produced conflicting results, including with regard to efficacy of treatment 219. 
The demonstration that a new pluripotent stem-cell type, namely induced pluripotent stem 
cells, may be generated from somatic cells, such as fibroblasts, by introducing the 
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transcription factors Oct3/4, Sox2, Klf4 and c-Myc, attracted a great deal of attention 220. 
Moreover, the observation that induced pluripotent stem cells may be induced to 
differentiate into motor neurons brought new hope for ALS 221. Nevertheless, whether these 
converted motor neurons can successfully rescue ALS awaits further validation 217. 
- RNAi is a process by which noncoding micro RNA (miRNA) inhibits and regulates gene 
expression by binding mRNA 222. Several hereditary neurodegenerative diseases are being 
targeted with RNAi therapy, including ALS 223. Gene suppression can be achieved with 
oligonucleotide approaches, such as RNAi and AONs. These methods have been tested only 
with two genes, SOD1 and Fas, and important results have been reported in animal models 
224. The only trial in patients with FALS resulting from a SOD1 mutation was started in 2010 by 
Isis Pharmaceuticals, involving injection of SOD1 inhibitor directly into cerebrospinal fluid. The 
main problem with these new drug strategies is delivery of gene regulators to the target cells 
because of the necessity of crossing the blood–brain barrier and of obtaining compounds with 
long-lasting effects 225. 
- Gene therapy with Vectors based on AAV and lentiviruses are proving to be particularly 
effective for the treatment of neurological disorders 226. These vectors are attractive for their 
simplicity and their high transduction efficiency for neurons 227. These vectors have been 
employed to deliver factors identified as crucial for neuronal survival such as IGF-1, G-CSF, 
ANG, or NT-3. These methods have not only been tested in small animal models, particularly 
in mice, but also in bigger animals such as cats and monkeys 228. 
All of these new approaches have yielded quite promising results, although much experimental 
work remains to be done to achieve effective therapy for ALS patients 225. 
1.9 High−throughput screening (HTS) approach based on multiple fluorescent 
probes to identify new drugs for treatment of Amyotrophic Lateral Sclerosis. 
The significant progresses in understanding the pathological mechanisms in ALS have not been 
matched with an effective disease-modifying pharmacotherapy. A critical step in designing more 
effective therapies for the treatment of neurodegenerative disorders, such as ALS, is the 
identification of drugs able to interfere with the first cellular alterations, prior to the onset of 
motoneuronal death. High−throughput experimental strategies (HTS) aimed at the finding of 
pharmacological compounds that might slow, stop or reverse disease progression may provide a 
unique and powerful tool for the indentification of new active drugs for treating ALS. 
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The main goal of HTS is to accelerate the discovery of new potential drugs using a fully automated 
robotic system able to screen a large libraries of compounds (genomic, protein and chemical 
libraries), in the range of 10.000-20.000 per day (100.000 data points generated per day for ultra-
highthroughput screening) 229. 
Crucial steps in performing successfully HTS approach are the choice of the appropriate 
technological platform but also of an adequate cellular model as basis for the biological assay 
chosen for the screening. To this purpose, the use of a cell-based assay, based on stable 
expression of sensitive fluorescent reporter able to monitor cellular toxicity induced upon 
expression of ALS causative genes by adenoviral delivery, could offer main advantages: i) the 
adenoviral delivery will allow an efficient ALS-causative gene expression; ii) fluorescence-based 
assays are widely used in HTS screening due to their high sensitivity, easy of both operation and 
readout; c) the screening of a large number of compounds would greatly increase the possibility of 
finding bioactive molecules, thus improving and accelerating drug design for ALS treatment. 
1.9.1 Redox sensitive Green Fluorescent Protein (roGFP). 
Reactive oxygen species, oxidative stress, and antioxidant levels are widely believed to play key 
roles in health and disease. The recent development of fluorescent proteins (FP) engineered to be 
biosensor of redox unbalance offered a unique opportunity of monitoring redox changes in both 
physiological and pathological context of living animals and plants. 
The first redox-sensitive FP (roFP), based on the yellow FP, was developed in 2001 by introducing 
two redox-active cysteins in position 149 and 202 (rxYFP149/202). The redox potential of the 
cysteine couple was found to be within the physiological range for redox-active cysteines, but the 
roYFP probe gives only an intensity change, not a ratiometric response 230. In 2004, James 
Remington 231 and Roger Tsien 232 describe the independent development of several GFP-based 
indicators of redox status that are ratiometric by excitation. They evaluate roGFP1 (GFP with 
mutations C48S, S147C, and Q204C) and roGFP2 (the same plus S65T, that enhance GFP 
chromophore) with physiologically or toxicologically relevant oxidants in mammalian cells, 
including HeLa and macrophages cells. In vitro and in vivo, roGFP1 and roGFP2 show two-state 
changes in fluorescence emission in response to the ambient thiol/disulfide ratio. roGFP indicators 
are ratiometric by excitation, that is, they exhibit two excitation peaks (at about 390 and 475 nm), 
corresponding to the neutral and anionic chromophore forms, respectively (Fig. 9). Excitation of 
either peak gives rise to green fluorescence at about 510 nm. Upon oxidation of the redox-
sensitive disulfide, the population of the neutral chromophore is favored at the expense of the 
anionic chromophore. Importantly, the redox-dependent fluorescence ratio exhibited by roGFP2 is 
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insensitive to pH changes in the physiological range 233. These indicators have been shown to be 
suitable for use in relative reducing subcellular environments such as mitochondria or the 
cytoplasm in both animal and plant cells 231,232. Different peptide signals have been used to drive 
the expression of roGFP sensors in mitochondria matrix and inner membrane space, with similar 
results. 
 
Figure 9: Key structural features of roGFP. A) Tridimensional structure of roGFP that highlights the amino acid 
modifications around the chromophore. B) Simulation through ball-and-stick model of disulfide bond between 
engineered residues Cys147 and Cys204. C) Fluorescence excitation spectra of roGFP. 
 
1.9.2 Yellow Fluorescent Proteinu (YFPu). 
Protein aggregates and ubiquitin/proteasome system (UPS) impairment are believed to play key 
roles in several disease such as neurodegenerative diseases, included ALS. 
The yellow fluorescent proteinu (YFPu) is a FP engineered to be biosensor to investigate the specific 
relation between protein aggregation and the function of the UPS. This reporter consisting of a 
short degron (ACKNWFSSLSHFVIHL), CL1 234, fused to the COOH-terminus of yellow fluorescent 
protein 235. In particular, the yellow fluorescent proteins (YFPs) were created by mutating Thr203 
of the Aequorea victoria green fluorescent protein (GFP) 236,237 to aromatic amino acids, typically 
Tyr. The resulting π-π stacking and increased local polarizability immediately adjacent to the 
chromophore are believed to be responsible for the 20-nm shift to longer excitation and emission 
wavelengths 238. The presence of short degron CL1 in fusion with the YFP makes this reporter a 
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good marker to UPS activity. In fact, in basal conditions this fusion-protein is rapidly degraded 
through the UPS system, while if the proteasome was altered (i.e. inhibitors, saturation due to 
misfolded proteins) occurs the accumulation of the protein, and then the fluorescence in the living 
cells 239(Fig. 10). 
 
Figure 10: Structure and function of YFP
u
. In basal cellular conditions, the YFP
u
 is degraded by the proteasome. The 
presence of proteasome inhibitors causes protein accumulation as well as fluorescence accumulation. 
 
1.9.3 DsRed-LC3-GFP reporter. 
Autophagy is an intracellular lysosomal degradation process, which plays an important role in cell 
growth and development, and keeping cellular homeostasis in all eukaryotes. Autophagy has 
multiple physiological functions, including protein degradation, organelle turnover and response 
to stress. Growing evidence supports a role of autophagic dysfunction as a contributing factor in 
various neurodegenerative diseases associated with abnormal aggregation of disease-related 
mutant proteins 197,240. 
The DsRed-LC3-GFP sensor is a dual colour reporter between two spectrally distinct fluorescent 
protein: the DsRed fluorescent protein, responsible for the red coloration around the oral disk of a 
coral of the Discosoma genus, the fluorescent protein with the longest excitation/emission 
spectrum yet reported for a wild-type spontaneously fluorescent protein (excitation and emission 
maxima at 558 and 583 nm, respectively) 241, in fusion with the classical GFP-tagged LC3 reporter 
242. This reporter provides two readouts for autophagy activity: the number of DsRed-LC3 puncta 
and a flow cytometric measurement (called autophagy index). Like previous results obtained using 
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a GFP-LC3 reporter, this reporter showed an increase in the number of DsRed-LC3 puncta upon a 
PBS incubation or amino acid deprivation. Moreover, the reporter GFP separated from the C-
terminus of LC3 by a recognition site for the autophagic protease, ATG4, and loss of GFP 
fluorescence can be monitored by decrease of GFP fluorescence or by flow cytometry (Fig. 11) 243. 
 
Figure 11: Schematic diagram showing the concept behind the DsRed-LC3-GFP autophagy reporter. When autophagy 
is activated, LC3 is cleaved to protease Atg4 in LC3II. Complex DsRed-LC3II is transported in the autophagosome 
membrane where is able to resist the acid pH, while the GFP is degraded. 
 
1.9.4 CFP-DEVD-GFP: FRET (Fluorescent Resonance Energy Transfer) reporter. 
Caspase-3 is a crucial component of apoptotic machinery in many cell type. Apoptosis, or 
programmed cell death, is responsible for many normal development processes. For example, it is 
crucial during embryonic development, in shaping the adult organism, in surveillance of the cell 
cycle, and in some forms of chemically induced cell death. Inappropriate apoptosis has been 
implicated in many human disease such as neoplasia, in acute organ failure and also 
neurodegeneration and evidences support the opinion that dysregulation of apoptotic pathway 
might be a key event for ALS pathogenesis 244. 
The development of mutants of GFP with distinct spectral properties, has allowed in vivo 
measurement of protein-protein interaction to be performed by measuring fluorescent resonance 
energy transfer (FRET). For example the emission spectrum of cyan fluorescent protein (CFP: GFP 
with mutations Y66W, F64L, S65T, N146I, M153T and V163A) overlaps significantly with the 
excitation spectrum of yellow fluorescent protein (YFP: a particular GFP variant called Venus with 
mutations F64L, M153T, V163A and S175G); placing CFP in close proximity to YFP (i.e. <5nm) 
allows FRET between the two fluorescent moieties to occur. Therefore, FRET between this two 
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spectrally distinct GFP mutants, fused with a peptide containing the sequence DEVD, which is 
cleaved by capsase-3 (Fig. 12) is a good sensor to monitor in living cells the activity of caspasi-3 
245,246. 
 
Figure 12: Structure and function of FRET reporter. A) Schematic diagram of CFP-DEVD-YFP fusion protein containing 
an 18 amino acid linker possessing the caspasi-3 specific cleavage sequence (DEVD). B) Schematic representation of 
electron vibrational energy states that occur during FRET and of the excitation spectrum overlap between  fluorescent 
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AIMS OF THE PROJECT. 
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Up to date, hypotheses on biology underlying both sporadic and familiar ALS forms in humans 
outline a model in which non-competing mechanisms are likely to converge in various 
unsuccessful patterns to mediate selective motoneuron degeneration. Unfortunately these 
significant progresses  in understanding the pathological mechanisms in ALS have not been 
matched with an effective disease-modifying pharmacotherapy. Moreover, in recent years the 
identification of TDP43 and FUS as ALS causative genes brought attention to the problems 
involved in RNA metabolism and protein aggregation. 
For this reason, I decided to focus my PhD project on two objectives: 
AIM 1: GFP-based reporters to monitor biochemical alteration in cellular models for ALS: a possible 
and straightforward read-out for high-throughput screening (HTS) assay. 
This objective is focused on the development of different cellular models expressing high sensitive 
fluorescent probes suitable for the HTS analysis of cell toxicity upon expression of ALS-causative 
genes (SOD1, TDP43 and FUS in their wild type or mutant form) driven by adenoviral system. 
AIM 2: Study of the pathophysiological mechanisms responsible for cellular toxicity of pathological 
forms of two RNA-binding protein, FUS and TDP43, in familial forms of ALS. 
Identification of TD43 and FUS as ALS causative genes and their strong structural and functional 
similarities suggest a common mechanism of pathogenicity. Therefore, I decided to explore the 
molecular mechanisms of toxicity induced by the expression of pathological forms of TDP43 and 
FUS in two directions: 
1) Identification of the RNA target of FUS.  
2) Study of the relationship between aggregation, alterations of the proteasome and autophagy as 
well as cell death in the presence of pathological forms of TDP43 and FUS. 
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MATERIALS AND METHODS. 
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Competent cells used are E. coli DH5 . Bacterial cells are defective for the restriction and have 
mutations in relA1 and recA1 genes, to improve the stability and quality of recombinant plasmids. 
Cell lines. 
SH-SY5Y cell line 247: SH-SY5Y cells (ATCC number CRL-2266) are human cells derived from 
neuroblastoma cell line. 
Adeno-X 293 cell line: Adenovirus 5-transformed Human Embryonic Kidney 293 cell line (HEK 293; 
ATCC, Rockville, MD, CRL 1573) is used to package and propagate the recombinant adenoviral- 
based vectors produced with the BD Adeno-X Expression System. 
Plasmid constructions and oligonucleotides. 
hFUSWT/R495X/H517G/R521G/P525L: Human cDNA coding for FUS (NM_004960.3) was cloned by reverse 
transcription-PCR from human SH-SY5Y neuroblastoma cells cDNA, using the forward primer 5’-
AATTCTCGAGCCGCCTCAAACGATTATACCCA-3’ and the reverse primer 5’-
AATTCTCGAGTTAATACGGCCTCTCCCTG-3’. The resulting PCR fragment was inserted into XhoI 
restriction site of pCS2-MTK vector. Mutants were obtained by mutagenesis starting from hTDP-













Table 2: Primer list used for mutagenesis of FUS cDNA. 
hTDP43WT/Q331K/M337V/A382T: Human cDNA coding for TDP43 (NM_007375.3) was cloned by reverse 
transcription-PCR from human SH-SY5Y neuroblastoma cells cDNA, using the forward primer 5’- 
AATTCTCGAGCCTCTGAATATATTCGGGTAACC-3’ and the reverse primer 5’- 
AATTCTCGAGCTACATTCCCCAGCCAGAA-3’. The resulting PCR fragment was inserted downstream 
to 5xMyc repeats into XhoI restriction site of the pCS2-MTK vector. Mutants were obtained by 
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mutagenesis starting from hTDP43, using the Quickchange site-directed mutagenesis kit 








Table 3: Primer list used for mutagenesis of TDP43 cDNA. 
roGFP: cDNA coding for roGFP was cloned by restriction reactions or PCR from pCVU55762-roGFP 
(kindly provided by Dr. Andreas J. Meyer, University of Heidelberg, Germany). The resulting 
fragment was insert into BamHI/NotI sites of pcDNA3, into PstI/XhoI sites of pCMV/myc/mito 
(mito: mitochondrial matrix localization signal) and into BamHI/EcoRV sites of pcDNA3-IMS (IMS: 
mitochondrial intermembrane space targeting sequence from mouse cyt-C1). All the plasmid 
constructions were verified by automated sequencing. 
YFPU: the pEYFP-C1 plasmid was kindly provided by Prof. Rusmini (University of Milan, Italy) 248. 
DsRed-LC3-GFP: the pQCXI Neo DsRed-LC3-GFP plasmid was purchased from Addgene company 
(cod. 31183). 
CFP-DEVD-YFP: the pECFP-DEVDR-Venus plasmid was purchased from Addgene company (cod. 
24537). 
Adenoviral vectors. 
All adenoviral vector (pAdenoX-hFUSWT/R495X/H517Q/R521G/P525L; pAdenoX-hTDP43WT/Q331K/M337V/A382T 
and pAdenoX-hSOD1WT/H80R/G93A) were generated using the Adeno-X Expression System 1 
(Clontech). Their production is completed in two stages. First, generation of mammalian 
expression cassette by cloning gene of interest into pShuttle2. Second, excision of expression 
cassette from pShuttle2 and insertion into I-Ceu I and PI-Sce I sites of BD Adeno-X Viral DNA. All 
constructions were verified by automated sequencing. 
Antibodies. 
In the present study we used the following antibodies: mouse anti-myc (clone 9E10 Sigma-Aldrich, 
1:5000 for western and 1:20000 for immunofluorescence), rabbit anti-Cu/Zn SOD1 (Enzo Life 
Science, 1:2000 final dilution), rabbit TARDBP (Proteintech, 1:1500 final dilution), mouse FUS/TLS 
(Santa Cruz Biotechnology, 1:1000 final dilution), rabbit anti-GFP (Enzo Life Science, 1:1000 final 
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dilution), rabbit anti-CREB (Santa Cruz Biotechnology, 1:1000 final dilution), mouse anti-β-actin 
(Sigma-Aldrich, 1:5000 final dilution), rabbit anti-PARP (Cell Signaling, 1:1000 for western and 
1:500 for immunofluorescence), rabbit antiLC3 (Cell Signaling, 1:1000 final dilution), Alexa 
Fluor®488 goat anti-mouse IgG (Life Technologies, 1:2000 final dilution), Alexa Fluor®647 goat 
anti-rabbit IgG (Life Technologies, 1:2000 final dilution), Goat anti-Mouse IgG Peroxidase 
conjugated (Millipore, 1:2500 final dilution), Goat anti-Rabbit IgG Peroxidase conjugated 
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3.2 METHODS. 
Standard technique of molecular biology. 
All standard technique of molecular biology were performed according to Molecular Cloning–A 
Laboratory Manual 249. 
DNA purification from agarose gel. 
Whenever it was necessary to purify DNA from agarose gel was used the commercial Kit Wizard ® 
SV Gel and PCR Clean-Up System (Promega) according to the manual instructions. 
Plasmid DNA purification. 
When it has been requested a greater quality of plasmidic DNA (i.e. sequence analysis or cell's 
transfection), was used the commercial kit Wizard®Plus SV Minipreps DNA Purification System 
(Promega) and PureLink® HiPure Plasmid Midiprep Kit (Life Technologies) according to the manual 
instructions. 
Cell cultures. 
SH-SY5Y are cultured in Dulbecco MEM/F12 ground (Gibco BRL), HEK293 in Dulbecco MEM (Gibco 
BRL), always in the presence of 10% fetal calf serum, free of tetracycline contamination (Tet-free 
FCS, Clontech) and inactivated at 56 °C for 30’. Medium contains 100 units/ml penicillin G and 100 
μg/ml streptomycin (Gibco BRL). The cells are grown in an incubator at 37 °C in a humidified 
atmosphere containing 5% CO2. Trypsin (0.5 g/ml, 68 mM EDTA) is added to split cells, then diluted 
in fresh medium. 
Transfection of eukaryotic cells. 
Transient expression of each plasmid (1.5 μg DNA/5–7×105 cells) is obtained transfecting cells with 
LipofectAMINE LTX and PLUS reagent (Life Technologies). Dilute the optimized amount of plasmid 
DNA in OPTIMEM (Gibco BRL) and add the optimized volume of PLUS™ Reagent directly to the 
diluted DNA. Mix gently and incubate for 5’ at room temperature. Add the optimized volume of 
Lipofectamine™ LTX directly to the diluted DNA, incubate for 30’ at room temperature. DNA-lipid 
complexes are stable for 6 hours at room temperature. Add DNA-lipid complex dropwise to the 
well containing cells, mixing gently. Medium may be changed after 4–6 hours. 
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Production of recombinant adenovirus. 
Plate HEK 293 cells at a density of 1–2 x 106 cells per 60-mm culture plate 12–24 hours before 
transfection and incubate the plate(s) at 37°C in a humidified atmosphere maintained at 5% CO2. 
Transfect each 60-mm culture plate with 5 µg of Pac I-digested BD Adeno-X DNA using standard 
transfection method. One day later, and periodically thereafter, check for cytopathic effect (CPE). 
One week later, transfer cells to a sterile 15-ml conical centrifuge tube (do not use trypsin: 
infected cells that still adhere to the bottom or sides of the culture plate can be dislodged into the 
medium by gentle agitation). Centrifuge the suspension at 1,500 x g for 5 min at room 
temperature. Resuspend the pellet in 500 µl sterile PBS. Lyse cells with three consecutive freeze-
thaw cycles: freeze cells in a dry ice/ethanol bath; thaw cells by placing the tube in a 37°C water 
bath (do not allow the suspension to reach 37°C). Vortex cells after each thaw. After the third 
cycle, briefly centrifuge to pellet debris. Transfer the lysate to a clean, sterile centrifuge tube and 
use immediately to infect a fresh 60-mm culture by adding 250 µl (50%) of the cell lysate directly 
to the medium, then incubate as normal. CPE should be evident within one week. Repeat these 
steps two or three time until get a high titer viral preparation. 
Determination of adenoviral titer: End-Point dilution assay. 
Approximately 24 hours before beginning the titration protocol, plate HEK 293 cells in two 96-well 
plates. Carefully seed all wells at the same density (~104 cells per well) in 100 µl of growth 
medium. Prepare serial dilutions of your virus as follows: 
- Make a 1:100 dilution by adding 10 µl virus stock to 990 µl sterile growth medium. 
- Starting with the 1:100 dilution, prepare serial 1:10 dilutions by transferring 100 µl diluted 
virus to 900 µl sterile growth medium. 
In general, an appropriate range of dilutions for testing is 10–3–10–10. Remove the 96-well culture 
plate from the incubator and inspect the wells to ensure that the cells have attached to form an 
even monolayer. Add 100 µl diluted virus to each well in columns 1–10 and add 100 µl of virus-
free growth medium to wells in columns 11–12, these wells serve as controls for the viability of 
non-infected cells. Cover the plate and incubate in a humidified CO2 (5%) incubator for 10 days at 
37°C. Using a microscope, check each well for cytopathic effect (CPE). For each row, count the 
number of wells having CPE. A well is scored as CPE positive even if only a few cells show 
cytopathic effects. If you are uncertain, compare the infected well with the non-infected control 
wells. Calculate the fraction of CPE-positive wells in each row. Finally, calculate Viral Titer:  
- Titer (pfu/ml) = 10(x + 0.8)  
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x = the sum of the fractions of CPE-positive wells.  
The assay is a reliable indicator of viral titer only if the following three conditions are met: i) the 
negative control wells show no visible signs of CPE or growth inhibition. ii) wells infected with the 
least dilute virus (10–3) are all CPE-positive. iii) wells infected with the most dilute virus (10–10) are 
all CPE-negative. 
Adenoviral infection of eukaryotic target cells. 
Plate target cells (SH-SY5Y cells or SH-SY5Y stably espressing YFPu, roGFP or mitochondrial targeted 
roGFP) 12–24 hours before infection in the culture plates desired. The next day, remove the 
growth medium and infect target cells diluting viruses at a multiplicity of between 5–30 pfu/cell in 
OPTIMEM (Gibco BRL). Cover the plates and incubate the cells in a humidified CO2 (5%) incubator 
at 37°C for 1 hour to allow the virus to infect the cells. Add fresh complete growth medium and 
incubate in a humidified 5% CO2 at 37°C. Analyze gene expression at different time points 
required then proceed to further experimental manipulations. 
CLIP (CrossLinking Immunoprecipitation). 
To identify potential RNA target of FUS, SH-SY5Y cells were subjected to CLIP method: 
Crosslink proteins-RNA, cell lysis and sonication. 
24h after infection with recombinant adenoviruses encoding for FUSWT, SH-SY5Y infected or 
uninfected cells (3.5x106 cells) were fixed in formaldehyde 4% for 10 minutes then lysed in 1,5ml 
of RIPA buffer [Tris HCl pH 7.5 50mM, NP-40 1%, DOC 0.5%, SDS 0.05%, EDTA 1mM, NaCl 150mM, 
protease inhibitors cocktail (Sigma-Aldrich) and RNasin (Promega)] and incubated for 20 minutes 
on ice. The lysate was sonicated for three cycles of 20 seconds and after centrifugation at 
12,000xg for 10 minutes at 4 °C, recover the supernatants. 
Immunoprecipitation. 
Pre-clear the supernatants at 4 °C for 1 h with protein A-Sepharose (Sigma-Aldrich). Add the anti-
Myc antibody at 1:1000 dilution, and after an overnight incubation at 4 °C, collect the 
immunoprecipitates by adding 20 μl of protein A-Sepharose (Sigma-Aldrich). Wash the beads five 
times in RIPA buffer, at last wash remove 100 μl of sample to control the immunoprecipitation 
then add Laemmli Buffer 5X and analyze by Western blotting. 
Reverse crosslink. 
After centrifugation of immunoprecipitates, resuspend the beads in 300 μl of RIPA buffer [Tris HCl 
pH 7.5 50mM, NP-40 1%, DOC 0.5%, SDS 1%, EDTA 1mM, NaCl 150mM, protease inhibitors 
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cocktail (Sigma-Aldrich) and RNasin (Promega)] and incubate the supernatants for 45 minutes at 
70°C. Centrifuge at 400xg at 4°C for 3 minutes and recover the supernatants. 
RNA extraction. 
After treatment for 15 minutes at 37 °C with Dnase (1U/µl, Promega) and RNase OUT (Promega, 
40U/μl), add to the samples Na-acetate pH4 (1/10 volume), phenol acid (1/2 volume) and 
chloroform (1/5 volume), shake tubes vigorously and incubate for 10 minutes on ice. Centrifuge 
the samples at 12,000 ×g for 10 minutes at 4°C. Following centrifugation, the mixture is separated 
into a lower phenol-chloroform phase, an interphase, and a colorless upper aqueous phase. RNA 
remains exclusively in the aqueous phase. Transfer the aqueous phase to a fresh tube. Precipitate 
the RNA from the aqueous phase by mixing with two volumes of absolute ethyl alcohol . Incubate 
samples overnight at -20°C and centrifuge at 12,000 ×g for 10’ at 4°C. Remove the supernatant 
and wash the RNA pellet once with 80% ethanol. Mix the sample by vortex and centrifuge at 
12000 ×g for 5’ at 4°C. At the end of the procedure, briefly dry the RNA pellet and dissolve RNA in 
10µl od RNase-free water and use its half for RT-PCR reaction. 
RT-PCR. 
Add 2µl of random hexamers (100ng/µl), heat at 65 °C for 5min to denature RNA secondary 
structure. Add 2,5µl of 2mM dNTPs, 2,5µl of 0.1M DTT, 0,5µl of SuperScript II RT (200 U/µl), 0,5 µl 
od RNase OUT (40 U/µl) and incubate at room temperature for 5min, at 37°C for one hour and 
95°C for 5min to inactivate reverse transcriptase. PCR settings as control to amplify C-terminal 
fragment of FUS sequence was set up as follows: 5min 95°C; 30 cycles of (30 s for 95 °C, 30 s for 58 
°C, and 40 s for 72 °C); and 10min 72 °C. Run the entire PCR and visualize amplified DNA. 
Cloning and screening of colonies. 
After RT-PCR, to generate dsDNA add random hexamers (100ng/µl), dNTPs (2mM) and Klenow 
(5U/µl, Promega) and incubate for 30min at 25°C then add T4 polymerase (10U/ µl, Promega) and 
incubate for 10min at 37°C. Phosphorylate dsDNA by treatment with T4 polynucleotide kinase 
(10U/µl, BioLabs) for 30min at 37°C with ATP as phosphate donor. Finally, clone all obtained 
dsDNA into EcoRV restriction site of pBluescript II SK (-) vector and transform in E.coli DH5α cells. 
Grow singularly all colonies and extract plasmidic DNA. Analyse presence of CLIP-insert by PCR 
using T3 and T7 primers (reaction settings was described previously). All positive samples was 
sequenced availing an external company. 
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Assessment of apoptosis and cell viability. 
Quantification of apoptotic cells was obtained by direct visual counting after nuclear staining of 
4% paraformaldehyde-fixed cells with the fluorescent probe Hoechst 33342 (1 mg/ml) (Sigma-
Aldrich). One hundred cells were examined for each field at a magnification of 200× and eight 
randomly chosen fields for each experimental condition were counted. Only the cells containing 
clearly picnotic or fragmented nuclei were considered apoptotic.  
The viability of control SH-SY5Y cells or SH-SY5Y cells infected with adenoviruses encoding for fALS 
causative genes was calculated after 72 hours through an MTS assay. Cell viability was assessed by 
a colorimetric assay using the 3(4,5-dimethylthiazol-2yl)-5-(3-carboxymethoxyphenyl)-2-(4- 
sulfophenyl)-2H-tetrazolium (MTS) assay (CellTiter 96 Aqueous One Solution Assay, Promega), 
according to the manufacturer’s instructions. Absorbance at 490 nm was measured in a multilabel 
counter (Victor X5, PerkinElmer). 
Nuclear-cytoplasmic separation. 
1×106 SH-SY5Y cells were transfected or not (-) with a plasmid coding for TDP43WT or TDP43M337V 
and TDP43A382T mutants. 72 h after transfection cells were wash twice with cold PBS 1X, harvested 
in 500 μl of PBS 1X and centrifuged at 1000 xg for 3 min at 4 °C. The pellet were resuspended 
gently in 500 μl of S1 buffer (10mM Hepes pH 7.9, 10mM KCl, 1.5mM MgCl2, 0.1mM EGTA pH 7.0, 
1M DTT (1 μl/2ml), and protease inhibitors mixture, Sigma-Aldrich). Syringe ten times at 4 °C and 
centrifuge at 1000 xg for 3’ at 4 °C, supernatant (cytoplasmic fraction) was collected and the pellet 
was resuspended gently in 500 μl of S1 buffer. Centrifuge at 3000 rpm for 3’ at 4 °C, the pellet was 
resuspended with 30μl of S2 (10mM Hepes pH 7.9, o.4M NaCl, 1.5mM MgCl2, 0.1mM EGTA pH 7.0, 
5% glycerol 1M DTT (1 μl/2ml), and protease inhibitors mixture, Sigma-Aldrich). Shake for 30 min 
at 4 °C, centrifuge for 10 min at 4 °C at 12,000xg and collect the supernatant (nuclear fraction). 
Solubility assay. 
5-7×105 SH-SY5Y cells were transfected or not (-) with a plasmid coding for TDP43WT or TDP43M337V 
and TDP43A382T mutants. 72 h after transfection cells were scraped off the plate in culture 
medium, collected by centrifugation, washed with PBS 1X, and resuspended in 150µl of buffer A 
(10mM Tris-HCl pH 8.0, 1mM EDTA pH 8.0, 100mM NaCl, 0.5% Nonidet-P40, and protease 
inhibitors mixture, Sigma-Aldrich). After 10 min of ice incubation, the lysates were centrifuged at 
20,000 xg for 10 min, and the supernatants were collected as detergent soluble fractions, whereas 
the pellet (insoluble fractions) was washed in PBS 1X and resuspended in 150µl of Laemmli sample 
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buffer (62mM Tris-HCl pH 6.8, 10% glycerol, 2% SDS, 5% β-mercaptoethanol, and 0.05% 
bromophenol blue). 
Immunofluorescence. 
Wash 1×105 SH-SY5Y cells, grown on a cover-glass, twice with PBS 1X and then fix with 1 ml of 4% 
paraformaldehyde/PBS 1X for 10’. Permeabilize cells with 0.1% Triton X-100 in PBS and block non-
specific binding with 5% bovine serum albumin, 0.1% Triton X-100 diluted in PBS for 1 h at room 
temperature. Incubate cells with primary antibodies diluted in blocking solution, overnight at 4 °C 
and then with secondary antibodies and nuclear marker (TO-PRO3, Life Technologies or Hoechst 
33342, Sigma-Aldrich), diluted in blocking solution for 1 h at room temperature. Analyze cells with 
a Leica TCS SP5 confocal microscopy with LAS lite 170 image software. 
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4.1 GFP-based reporters to monitor biochemical alteration in cellular models for 
ALS: a possible and straightforward read-out for high-throughput screening (HTS) 
assay. 
A critical step in designing more effective therapies for the treatment of neurodegenerative 
disorders, such as Amyotrophic Lateral Sclerosis (ALS), is the identification of drugs able to 
interfere with the first cellular alterations, prior to the onset of motoneuronal death. 
High−throughput experimental strategies (HTS) aimed at finding pharmacological compounds that 
might slow, stop or reverse disease progression may provide a unique and powerful tool to 
identify new active drugs for treating ALS. Such technologies rely on the availability of automated 
cell-based assays and screening protocols to fulfill all the requirements needed for HTS 
procedures. 
To this purpose, we have generated different cellular models where specific markers of cell 
toxicity, induced by expression of ALS-causative genes, would be used as a straightforward read-
out for high-throughput screening of compound libraries of different nature. In particular, the 
general strategy showed in figure 13 has been proposed. 
 
Figure 13: ALS cellular models experimental strategy. 
Sonia Esposito                      Physiopathology of ALS: from oxidative stress to RNA metabolism.                                 Pag. 50 
PhD Thesis in Biomolecular and Biotechnological Science 
University of Sassari 
 
As shown in figure 13 neuronal SH-SY5Y cells expressing high sensitive fluorescent probes suitable 
for measurement of i) oxidative stress; ii) ubiquitin proteasome system impairment; iii) autophagy 
activation; iv) caspasi-3 activation, which have been described to be key events during ALS disease 
progression. These biological effects have been evaluated upon adenoviral delivery of ALS disease 
causative genes SOD1, TDP43 and FUS in wilt type or mutant form. 
4.1.1 Adenoviral delivery of ALS-causative genes. 
In order to identify molecules able to intercept the cellular damage generated by the expression of 
ALS causative genes, different cellular models able to mimic the genetic alterations that cause fALS 
were built by the overexpression of SOD1 (OMIM # 105400), TDP43 (OMIM # 612069) and FUS 
(OMIM # 608030), respectively. In particular, both WT and mutant variants of the mentioned 
genes (Table 4) were expressed, described to be pathological mutations. 
fALS OMIM Gene Pathological mutations 
ALS1 # 105400 SOD1 G93A, H80R 
ALS6 # 608030 FUS R495X, H517G, R521G, P525L 
ALS10 # 612069 TDP-43 Q331K, M337V, A382T 
Table 4: fALS associated genes chosen for adenoviral delivery. Data extracted from the web site OMIM (Online Mendel 
Inheritance in Man). 
 
To drive the expression of ALS causative genes, the recombinant adenoviruses encoding for 
hTDP43 (WT or mutant) and hFUS (WT or mutant) genes were produced, since adenoviral driven 
expression of WT or mutant SOD1 in neuronal cell lines have been demonstrated to provide a 
good ALS-cellular model 250 and Ad hSOD1 particles were already available in the laboratory. 
Recombinant adenoviruses, in fact, provide a versatile system for gene expression studies and 
therapeutic applications. Since infection by adenovirus is not cell-cycle dependent, it is possible to 
deliver the gene of interest to primary as well as to transformed cell lines. Following infection, 
target gene was transiently expressed at high levels since many cells received multiple copies of 
the recombinant genome. Expression is transient because adenoviral DNA normally does not 
integrate into the cellular genome. 
The assembly of recombinant adenoviruses is completed in few stages: first the cDNA coding for 
TDP43 and FUS cDNA WT or bearing a pathological mutation was cloned into pShuttle2 vector, in 
fusion with five repeats of myc epitope (5xMyc). Second the expression cassette was excised from 
recombinant pShuttle2 plasmid DNA by digesting with I-Ceu I and PI-Sce I and ligated to Adeno-X 
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Viral DNA. Recombinants were selected with kanamycin and screened by restriction endonuclease 
digestion as shown in figure 14. 
 
Figure 14: Production of recombinant adenoviruses with the BD Adeno-X™ Expression System 1 (Clontech). Control 
digestion with XhoI of positive recombinant adenoviruses. M = molecular weight marker; 1,6 = pAdeno-X vector; 2 = 
TDP43
WT
; 3 = TDP43
Q331K
; 4 = TDP43
M337V
; 5 = TDP43
A382T
; 7 = FUS
WT
; 8 = FUS
R495X
; 9 = FUS
H517G
; 10 = FUS
R521G





Third, the recombinant adenoviral construct was cleaved with PacI to expose its inverted terminal 
repeats and transfected into a packaging cell line HEK293. After 7–10 days, viruses were harvested 
and amplified by infecting packaging cells for three times to obtain high titer virus stock. By 
performing an end-point dilution assay, the final yields were evaluated generally around 108 
plaque-forming particles per ml (Tab. 5). 
 
x = the sum of the fractions of 
CPE-positive wells 
Titer (pfu/ml) = 10(x + 
0.8) 
AdSOD1WT 5 3.2 x 108 pfu/ml 
AdSOD1G93A 9.9 6.3 x 108 pfu/ml 
AdSOD1H80R 7.9 5 x 108 pfu/ml 
AdTDP43WT 9.9 6.3 x 108 pfu/ml 
AdTDP43Q331K 4.9 3.1 x 108 pfu/ml 
AdTDP43M337V 3.9 2.5 x 108 pfu/ml 
AdTDP43A382T 2.4 1.5 x 108 pfu/ml 
AdFUSWT 7,1 4.5 x 108 pfu/ml 
AdFUSR495X 4.9 3.1 x 108 pfu/ml 
AdFUSH517G 4.9 3.1 x 108 pfu/ml 
AdFUSR521G 12 7.9 x 108 pfu/ml 
AdFUSP525L 5 3.2 x 108 pfu/ml 
Table 5: Determination of viral titer for all infectious recombinant adenoviruses encoding for fALS causative genes. 
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Recombinant adenoviruses were finally used to infect neuronal SH-SY5Y with a multiplicity of 
infection (M.O.I.) of 30 pfu/cell. Forty-eight hours after infection cells were harvested and protein 
extracts analyzed by Western Blot (Fig. 15). 
 
Figure 15: Cell lysates of SH-SY5Y cells after 48 hour following infection with 30 pfu/cell of infectious recombinant 
adenoviruses. Expression levels of genes of interest were evaluated by western blot analysis with anti-SOD1 antibody 
(A), anti-FUS antibody (B) and with anti-TDP43 antibody (C). 
 
As shown in figure 15 we were able to produce successfully an high titer of infectious recombinant 
adenoviruses for all fALS genes. 
4.1.2 Characterization of fALS cellular models. 
As an initial step to characterize the effects of adenoviral delivery of fALS genes into neuronal cells 
we evaluated metabolism and morphology of SH-SY5Y cells after infection with scalar 
concentration of infectious adenoviruses encoding for WT or mutant fALS genes through western 
blot analysis on total lysates or by immunofluorescence experiments. The cellular viability was 
analyzed performing a viability assay using a commercial kit (CellTiter 96® AQueous One Solution 
Cell Proliferation Assay, Promega). Neuronal SH-SY5Y cells were infected with increasing 
concentrations of adenoviruses encoding for WT or mutant fALS genes and 72 hours post-infection 
the MTS assay was performed, according to the manual instruction (Fig. 16). 
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Figure 16: SH-SY5Y cells were infected with increasing concentrations of recombinant adenoviruses encoding wild type 
or mutant fALS genes. After 72h, MTS tetrazolium compound (Owen’s reagent) was added to the cells and the plate 
was incubated at 37°C for 1–4 hours in a humidified, 5% CO2 atmosphere and then the absorbance was recorded at 
490nm. The quantity of formazan product is directly proportional to the number of living cells in culture. 
 
As shown in figure 17A, the western blot analysis in neuronal cells after 72 hours of infection 
showed that recombinant adenoviruses are able to drive expression of human TDP43 in WT form 
or carrying the mutations Q331K, M337V and A382T, despite slightly different levels. The 
immunofluorescence experiments showed that TDP43WT and TDP43Q331K mutant are normally 
localized to the nucleus, however both mutants, TDP43M337V and especially TDP43A382T showed a 
redistribution in the cytoplasm associated with apoptotic nuclei (Fig. 17B). Finally, the 
overexpression of both wild type and mutant forms of TDP43 induced a drastic reduction of cell 
proliferation in a dose-dependent manner, according with data so far available in literature 120 (Fig 
17C). 
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Figure 17: Effects of overexpression of wild type or mutant TDP43 gene on neuronal cells. A) Neuronal SH-SY5Y cells 
infected with increasing concentrations (5-15-30 pfu/cell) of adenoviruses encoding for WT or mutant TDP43 were 
analyzed 72h post-infection by western blot to evaluate expression levels of TDP43 (wild type or mutants). B) 72 hours 
post infection SH-SY5Y cells were subjected to immunofluorescence analysis with anti-myc (green) antibody to verify 
expression levels and localization of protein, anti-TOPRO-3 (grey) was used as nuclear marker. C) Neuronal SH-SY5Y 
cells infected with the indicated adenoviruses were analyzed 72h post-infection for quantity of formazan product 
directly proportional to the number of living cells in culture. 
 
Similarly, figure 18A showed that also infectious recombinant adenoviruses are able to drive 
expression of human FUS in WT form or carrying the mutations R495X, H517G, R521G and P525L, 
72 hours post-infection in neuronal cells. The immunofluorescence experiments showed that 
FUSWT is typically localized to the nucleus, and that all mutants, although in different ways, show a 
redistribution in the cytoplasm. This cytoplasmic relocation is particularly clear in FUSR495X and 
FUSP525L (Fig. 18B). Furthermore, the overexpression of FUSR495X, but not of wild-type FUS and 
other mutants, induces a significant reduction of cell proliferation, as assessed by MTS assay, 
which becomes evident at 72 hours after infection and only with the increase of recombinant 
adenovirus concentration (Fig. 18C). 
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Figure 18: Effects of overexpression of wild type or mutant FUS gene on neuronal cells. A) Neuronal SH-SY5Y cells 
infected with increasing concentrations (5-15-30 pfu/cell) of adenoviruses encoding for WT or mutant FUS were 
analyzed 72h post-infection by western blot analysis to evaluate expression levels of FUS (wild type or mutants). B) 72 
hours post infection SH-SY5Y cells were subjected to immunofluorescence analysis with anti-myc (green) antibody to 
verify expression levels and localization of protein, anti-TO-PRO-3 (grey) was used as nuclear marker. C) Neuronal SH-
SY5Y cells infected with the indicated adenoviruses were analyzed 72h post-infection for quantity of formazan product 
directly proportional to the number of living cells in culture. 
 
The effects of expression of WT or mutant SOD1 in neuronal cell lines through adenoviral delivery 
have been already demonstrated 250. However, as shown in figure 19 we were able to produce 
recombinant adenoviruses to drive expression of human SOD1 in WT form or with pathological 
mutations H80R and G93A. Moreover, 48 and 72 hours after infection with infectious 
adenoviruses encoding for SOD1 mutants, as expected, we detected increase in accumulation of 
fragmented nuclei, suggestive of an ongoing apoptotic process. 
 
Figure 19: Mutants of human SOD1 induce accumulation of fragmented nuclei in SH-SY5Y cells. (A) Neuronal cells 
infected with increasing concentrations (5-15-30 pfu/cell) of adenoviruses encoding for WT or mutant SOD1 were 
analyzed 72h post-infection by western blot to evaluate expression levels of SOD1 (wild type or mutants). B) SH-SY5Y 
cells were infected with adenoviruses coding for wild-type SOD1 or H80R and G93A-SOD1 mutants. After 48-72 h, 
nuclei of cells were stained with Hoechst 33342, and apoptotic nuclei were quantified as described in Materials and 
Methods. 
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4.1.3 Construction and characterization of neuronal cell lines stably expressing fluorescent 
reporter genes to assess in vivo different parameters of cell toxicity induced by ALS−causative 
genes. 
As mentioned in the Introduction, motoneurons in both sporadic and familiar ALS degenerate with 
overlapping molecular mechanisms that involve oxidative stress, alteration of proteasome activity 
and, ultimately, autophagy and apoptosis. Major advances in biotechnology have provided 
powerful tools to monitor in vivo all these markers of cell damage. In particular, we planned to 
use: 
− redox−sensitive GFP (roGFP) to monitor oxidative stress 251. 
− YFPu to monitor alterations in the activity of ubiquitin−proteasome system 248. 
− DsRed-LC3-GFP to monitor alterations of autophagy pathway 243. 
− FRET−based caspase−3 biosensors to follow apoptosis 252. 
4.1.3.1 SHSY5Y cells stably expressing redox−sensitive GFP (roGFP) to monitor oxidative stress 
either in the cytoplasm or in the mitochondria. 
As reported in the Introduction, disruption in cellular oxidation/reduction (redox) regulation is 
implicated in the pathogenesis of neurodegenerative disorders, including ALS. To monitor 
oxidative stress induced by overexpression of ALS causative genes, stable clones of neuronal 
SHSY5Y cells expressing the roGFP or mitochondrial targeted (mito and IMS) roGFP reporter have 
been produced. Stable cell lines were selected and the expression levels of cytosolic and 
mitochondria-targeted roGFP were evaluated by western blot analysis and autofluorescence (Fig. 
20). 
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Figure 20: A) Structural features of roGFP. This reporter was constructed by engineering four aminoacid residues of 
GFP
WT
. The cysteines Q204C and S147C form a disulfide cross-link between adjacent β-strands near the chromophore, 
which causes a internal structural rearrangements, so that the neutral chromophore is favored over the anionic. 
Therefore, as a population of roGFP is oxidized, disulfide formation leads to an increase in the excitation peak at 
405nm at the expense of the 480nm peak, the 405/480 excitation ratio is an indicator of the ambient cellular redox 
potential 
231 253
. Cell lysates of SH-SY5Y cell line stably expressing roGFP or mitochondrial targeted (mito and IMS) 
roGFP were subjected to western blot (B) with anti-GFP antibodies and autofluorescence analysis (C) to evaluate 
expression level and localization of roGFP. 
 
To evaluate ability of these stable clones to monitor in vivo cellular redox state, the 405/480nm 
excitation ratio (with emission measured at 508nm) was measured in the presence of excess 
exogenous membrane permeable oxidants (H2O2) or reductants (DTT). Fluorescent emission was 
detected through a microplates reader (Victor X5, Perkin Elmer) (Fig. 21). 
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Figure 21: Validation of the probe: variations of cellular redox state in living SH-SY5Y cells expressing roGFP (A), IMS-
roGFP (B) and mito-roGFP (C) after treatment for 30’ with scalar concentrations of exogenous oxidants and 
subsequent treatment for 15’ with reductants (DTT 10mM). Cellular redox state was expressed as 405/480nm 
excitation ratio (with emission measured at 508nm). 
 
As expected, the addition of H2O2 determined immediate oxidation of roGFP, detectable by 
increase of 405/480nm excitation ratio. Over time a slight decrease in oxidation level could be 
observed, although only the addition of DTT 10mM took it back to basal level. 
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4.1.3.2 Construction and characterization of SHSY5Y cells stably expressing YFPu to monitor 
alterations in the activity of ubiquitin−proteasome system. 
Accumulation of aggregated proteins and impairment of ubiquitin/proteasome system (UPS) are a 
key feature of the pathology of all the major neurodegenerative diseases, included ALS. To 
measure the UPS function in living cells, neuronal SHSY5Y cells stably expressing the YFPu reporter 
(Fig. 22A) have been generated. Stable cell lines were selected and the expression levels of YFPu, 
was evaluated by western blot analysis and autofluorescence after treatment with proteasome 
inhibitors MG132 or lactacystin (Fig. 22B and 22C). 
 
Figure 22: A) Structural features of YFP
u
: This reporter was created by mutating Thr203 of GFPWT to aromatic amino 
acids, typically Tyr, and by fusion of a short Degron, CL1, to the COOH-terminus of the protein, which sends the 
protein at degradation through UPS system. Cell lysates of SH-SY5Y cell line stably expressing YFP
u
 were analyzed 
treating the cells with proteasome inhibitors (MG132 and lactacystin 15µM for 4 hours). The accumulation of YFP
u
 was 
analyzed by western blot (B) with anti-GFP antibodies and autofluorescence experiments (C)  
 
As predictable, treatment with proteasome inhibitors determined accumulation of YFPu, 
suggesting impairment of UPS system. 
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4.1.3.3 Construction and characterization of SHSY5Y cells stably expressing DsRed-LC3-GFP to 
monitor autophagy. 
Autophagy is an intracellular lysosomal degradation process, which plays an important role in cell 
growth and development, and keeps cellular homeostasis in all eukaryotes (Fig. 23A). Emerging 
evidences support the notion that dysregulation of autophagy might be critical for pathogenesis of 
ALS. To monitor autophagy activation, stable clones of neuronal SHSY5Y cells expressing DsRed-
LC3-GFP reporter have been produced (Fig. 23B). Stable cell lines were selected and the 
expression levels of DsRed-LC3-GFP were evaluated by autofluorescence experiments (Fig. 23C) 
after treatment of 4 hours with proteasome inhibitor MG132. 
 
 
Figure 23: A) The autophagic process: Autophagy is characterized by the formation of a double-membrane delivery 
vesicle, the autophagosome. At present, microtubule-associated light chain 3-II (LC3-II) is the major protein marker 
specifically associated with the autophagosome in eukaryotes 
242
. B) Schematic diagram showing the concept behind 
the DsRed-LC3-GFP autophagy reporter: when autophagy is activated, LC3 is cleaved to protease Atg4 in LC3II. 
Complex DsRed-LC3II is transported in the autophagosome membrane where is able to resist to the acid pH, while the 
GFP is degraded. C) SH-SY5Y cell line stably expressing DsRed-LC3-GFP was analyzed by autofluorescence experiments 
before and after treatment with inhibitor proteasome (MG132 1µM for 4 hours). 
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As expected, treatment with proteasome inhibitor determined cleavage of LC3 and the resulting 
red autofluorescence accumulation in the autophagosome membrane while the GFP is degraded, 
suggesting activation of autophagy pathway. 
4.1.3.4 Construction and characterization of SHSY5Y cells stably expressing CFP-DEVD-YFP to 
monitor caspase-3 activation. 
Apoptosis is responsible for many normal development processes as embryonic development, in 
shaping the adult organism, in surveillance of the cell cycle, and in some forms of chemically 
induced cell death. Inappropriate apoptosis has been implicated in many human disease such as 
neurodegeneration and evidences support the opinion that dysregulation of apoptotic pathway 
might be a key event for ALS pathogenesis. The activation of caspasi-3 is a central event in the 
apoptotic process. To monitor apoptosis activation through cleavage of capsase-3, stable clones of 
neuronal SHSY5Y cells expressing CFP-DEVD-YFP reporter (FRET: fluorescence resonance energy 
transfer) have been produced. Stable cell lines were selected and the expression levels of CFP-
DEVD-YFP were evaluated by western blot experiments (Fig. 24C) after induction of apoptosis 
through nutrients deprivation (HBSS: Hank's Balanced Salt Solution) or stausporine. 
 
 
Figure 24: A) Schematic diagram showing the concept behind the CFP-DEVD-YFP reporter: the emission spectrum of 
cyan fluorescent protein (CFP) overlaps with the excitation spectrum of yellow fluorescent protein (YFP), placing CFP 
in proximity to YFP (i.e. <5nm) allows FRET between the two fluorescent moieties to occur. When induced apoptosis 
occurs the cleavage of DEVD sequence through caspase-3 protease and the decrease in FRET signal. B) SH-SY5Y stable 
Sonia Esposito                      Physiopathology of ALS: from oxidative stress to RNA metabolism.                                 Pag. 62 
PhD Thesis in Biomolecular and Biotechnological Science 
University of Sassari 
 
clones expressing CFP-DEVD-YFP were analyzed by western blot before or after induction of apoptosis through 
nutrients deprivation (HBSS for 2 hours) or treatment with stausporine (Stau 1µM for 2 hours). 
 
As shown in figure 24B, treatment with stausporine determined cleavage of DEVD target sequence 
and the resulting separation of two fluorescent protein, suggesting a probable activation of 
caspasi-3. 
4.1.4 Measure cell toxicity induced by ALS causative genes expression using fluorescent markers. 
In order to evaluate the possibility of using neuronal cell lines expressing roGFP, cytoplasmic or 
mitochondrial, or YFPu such as cellular system in HTS assays (see Introduction), several in vivo 
experiments have been performed using different cellular models to monitor the biological 
damage induced by the expression ALS-causative genes driven by adenoviral system. 
Firstly, to set out the in vivo experiments, stable cell lines espressing roGFP or mitochondrial 
targeted (mito and IMS) roGFP were infected with recombinant adenoviruses (M.O.I.  of 30 
pfu/cell) encoding for wild type SOD1 or with the pathological mutations H80R and G93A. After 24, 
48 or 72 hours of infection, the cells were analyzed in a microplates reader (Victor X5 -
PerkinElmer) to evaluate the cellular redox state as 405/480nm excitation ratio and the same cells 
were lysed and analyzed by western blot to verify expression levels of SOD1 genes and roGFP.  
As shown in figure 25A, after 24 or 48 hours of infection the overexpression of SOD1 with H80R 
pathological mutation induced a significant increase in the 405/480nm excitation ratio in stable 
cells espressing cytoplasmic roGFP when compared to wild type SOD1 or G93A mutant, to indicate 
that H80R mutant is able to induce oxidative stress in cellular environment. 72 hours post-
infection, a drastic fall in the 405/480nm excitation ratio was observed in all samples likely to 
indicate a general state of cellular impairment. Also in neuronal cells stably espressing the 
mitochondrial variant mito-roGFP (Fig. 25B) only the overexpression of H80R mutant increased the 
405/480nm excitation ratio after 24 or 48 hours of infection. Instead any significant change in the 
405/480 nm excitation ratio was observed in stable cells expressing the other mitochondrial 
variant IMS-roGFP (Fig. 25C), to indicate that this system probably is not able to detect changes in 
the cellular redox state. Figure XD shows the increase in SOD1 expression over time (24-48-72 
hours) and the expression levels of cytoplasmic roGFP in stable clone, similar results were also 
obtained on neuronal SH-SY5Y cells stably expressing two mitochondrial variants of roGFP (mito-
roGFP and IMS-roGFP) (data not shown). 
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Figure 25: Time course on SH-SY5Y stably expressing roGFP cytoplasmic or mitochondrial (mito-roGFP or IMS-roGFP), 
to monitor the biological damage induced by the expression of SOD1 gene driven by adenoviral system. The graphs 
show the changes in the cellular redox state in the cells (SHSY5Y) expressing (A) roGFP, (B) mito-roGFP and (C) IMS-
roGFP after exposure for 24-48-72 hours to the proper concentration of adenoviruses encoding for SOD1 gene in wild 
type form or with pathological mutations indicated. The fluorescence intensity was assessed using a microplates 
reader (Victor X5, Perkin Elmer), and the cellular redox state expressed as the ratio between the emission following 
excitation at 405nm and 480nm (with emission at 535nm). D) Representative western blot analysis using antibodies 
anti-SOD1 to verify comparable expression levels of SOD1 gene wild type or mutants over time. Antibody anti-GFP was 
used to verify the presence of roGFP reporter in stable cell expressing cytoplasmic roGFP and as a control of protein 
concentration. 
 
At this point of the study, similar experiments were carried out by choosing the optimal conditions 
found from previous experiments. Therefore neuronal cells stably espressing cytoplasmic roGFP 
and mito-roGFP were infected with 30 pfu/cell of recombinant adenoviruses encoding for the 
other fALS genes, wild type TDP43 or with pathological mutations Q331K and M337V and wild 
type FUS or with pathological mutations H517G and R521G. After 48 hours of infection, neuronal 
cells were analyzed in a microplates reader (Victor X5 PerkinElmer) and expressed cellular redox 
state as the 405/480nm excitation ratio. Then, the same cells were lysed and analyzed by western 
blot to verify expression levels of ALS-causative genes and roGFP. 
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Figure 26: In vivo assay on SH-SY5Y stably expressing roGFP to monitor the biological damage induced by the 
expression of fALS-causative genes driven by adenoviral system. A) The graph shows the changes in the cellular redox 
state in the cells (SHSY5Y) expressing roGFP after exposure for 48 hours to the proper concentration of adenoviruses 
encoding for all three ALS-causative genes in their wild type or with pathological mutations indicated. The 
fluorescence intensity was assessed using a microplates reader (Victor X5, Perkin Elmer), and the cellular redox state 
expressed as the ratio between the emission following excitation at 405nm and 480nm (with emission at 535nm). B) 
Western blot analysis using antibodies anti-TDP43 and anti-FUS to verify comparable expression levels of all two ALS-
causative genes wild type or mutants. Antibody anti-GFP was used to verify the presence of roGFP reporter and as a 
control of protein concentration (C). 
 
As shown by the graph in figure 26A, the overexpression of FUS with pathological mutation R521G, 
induced a significant increase in the 405/480nm excitation ratio when compared with expression 
of the wild type FUS or H517G mutant, to indicate that R521G mutant is able to induce oxidative 
stress in cellular environment. Instead the overexpression of wild type TDP43 or with the 
pathological mutations, Q331K and M337V, did not induced any alteration of 405/480nm 
excitation ratio, to indicate that this cellular model probably is not able to evaluate oxidative stress 
induced by overexpression of this gene. Similar results were also obtained on neuronal SH-SY5Y 
cells stably expressing the mitochondrial variants mito-roGFP, while stable clones expressing IMS-
roGFP are not able to detect changes in the cellular redox state (data not shown). 
Using the same experimental strategy described in the experiment of roGFP, 48 hours post-
infection the neuronal SH-SY5Y cells stably espressing YFPu reporter, able to monitor UPS activity, 
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were analyzed in a microplates reader (Victor X5 -PerkinElmer) to evaluate the fluorescence. Then, 
the same cells were lysed and analyzed by western blot to verify expression levels of ALS-causative 
genes and accumulation of YFPu. 
 
 
Figure 27: In vivo assay on SH-SY5Y stably expressing YFP
u
 to monitor the biological damage induced by the expression 
of ALS-causative genes driven by adenoviral system. A) The graph shows the changes in fluorescence intensity in the 
cells (SHSY5Y) expressing YFP
u
 after exposure for 48 hours to the proper concentration of adenoviruses encoding for 
all three ALS-causative genes in their wild type or with pathological mutations indicated. The fluorescence intensity 
was assessed using a microplates reader (Victor X5, Perkin Elmer), with excitation at 500nm. B) Western blot analysis 
using antibodies anti-SOD1, anti-TDP43 and anti-FUS to verify comparable expression levels of all three ALS-causative 
genes wild type or mutants. Antibody anti-GFP was used to verify the accumulation of YFP
u
 reporter (C). 
 
As shown by the graph in figure 27A, the overexpression of SOD1 with pathological mutation H80R 
induced a significant increase in fluorescence intensity when compared with expression of the wild 
type SOD1 or G93A mutant, suggesting that the presence of H80R mutation is probably able to 
impair the UPS activity resulting in accumulation of the protein. Also the overexpression of TDP43 
with the pathological mutation M337V and the overexpression of FUS with pathological mutation 
H517G increased the fluorescence intensity when compared with expression of the respective wild 
type or the other mutants. But when the YFPu accumulation was evaluated by western blot 
analysis (Fig. 27C), it has been showed that even the expression of the other mutants G93A of 
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SOD1, Q331K of TDP43 and H517G of FUS, as well as the overexpression of TDP43 and FUS in their 
wild type form caused the YFPu accumulation. This mismatch between data obtained by 
microplates reader and those obtained by western blot analysis is probably due to the pro-
aggregative properties of both wild type or mutant FUS and TDP43. The possible presence of these 
aggregates may interfere with the instrumental reading of fluorescence. 
Finally, we decided to monitor YFPu accumulation through autofluorescence experiments. 48 
hours after infection with adenoviruses encoding for all fALS genes, neuronal cells stable 
espressing YFPu were analyzed by confocal microscopy. 
 
 
Figure 28: Autofluorescence analysis on SH-SY5Y stably expressing YFP
u
 to monitor the biological damage induced by 
the expression of ALS-causative genes driven by adenoviral system. Cells (SHSY5Y) expressing YFP
u
 were infected 
adenoviruses encoding for all three ALS-causative genes in their wild type or with pathological mutations indicated. 48 
hours after infection the autofluorescence accumulation was detected by confocal microscopy. All images were 
acquired using the laser at the same power. 
 
Figure 28, in agreement with the western blot analysis data (Fig. 27C), shows that overexpression 
of all fALS causative genes is able to induce YFPu accumulation although in different ways. In fact, 
expression of wild type form of SOD1, TDP43 and FUS as well as of some mutants (H80R-SOD1, 
Q331K and M337V-TDP43 and H517G-FUS) induces a slight fluorescence accumulation in most 
cells and only a 10-20% of cells showed a marked and generalized fluorescence accumulation if 
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compared with the same cells untreated or treated with UPS inhibitor (lactacystin). Instead, G93A-
SOD1 and R521G-FUS expression induced on at least 80% of cells a more marked fluorescence 
accumulation. 
Probably, this cellular models is not suitable for an instrumental reading of the assay. 
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4.2 Study of the pathophysiological mechanisms responsible for cellular toxicity of 
pathological forms of two RNA-binding protein, FUS and TDP-43, in familial forms 
of ALS. 
In recent years the identification of TDP4392 and FUS70,71 as ALS causative genes drew attention 
on two problems closely linked to each other: (i) the presence of protein aggregates linked and/or 
caused by the proteolytic systems alteration; (ii) the RNA metabolism alteration, resulting in the 
relocation TDP43 and/or FUS in the cytoplasm. 
The strong structural and functional similarities between TDP43254 and FUS255, which are both 
proteins able to bind DNA and RNA , suggested a common mechanism of pathogenicity. The two 
current hypotheses involve both an abnormal RNA metabolism60 and an accumulation in 
cytoplasmic insoluble aggregates of mutant TDP43 and/or FUS with the consequent neuronal 
death. However, the mRNA targets of these two genes as well as the functional role of the 
aggregates in neurodegeneration are still unknown. Therefore, this project aims to explore the 
molecular mechanisms of toxicity induced by the expression of pathological forms of TDP- 43 and 
FUS in two main directions: 
1. Identification of the RNA target of FUS. 
2. Study of the relationship between aggregation, proteins localization, autophagy and cell 
death alterations in the presence of pathological forms of TDP43. 
4.2.1 Identification of the RNA target of FUS. 
Several lines of evidence suggested an involvement of FUS in multiple steps of RNA metabolism 
including transcription, splicing or transport of mRNA60, as well as microRNA metabolism66. 
Misregulation of RNA processing has been described in a growing number of neurological 
diseases256. The recognition of FUS as a central player in neurodegeneration, and the recent 
identification of ALS-causing mutations in TDP4392, another RNA/DNA binding protein, has 
reinforced a crucial role for RNA processing regulation in neuronal integrity. However, a 
comprehensive protein-RNA interaction map for FUS and identification of post-transcriptional 
events that may be crucial for neuronal survival remains to be established. 
4.2.1.1 CLIP (CrossLinking ImmunoPrecipitation) to identify RNA partners of FUS. 
To identify potential RNA target of FUS protein I set out to develop a variant of CLIP (Cross-Linking 
Immune-Precipitation) technique on SH-SY5Y cells infected with adenovirus encoding for this ALS 
causative gene in wild-type form or with pathological mutations (Fig.29). 
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Figure 29: A schematic representation of CLIP procedure for identification of RNA partners of FUS protein in the 
context of intact cells. Neuronal SH-SY5Y cells adherent are treated with formaldehyde, leading to formation of a 
interactions between protein and RNA. Cells were lysed in RIPA buffer and the lysate was subjected of sonication 
(three cycles of 30 seconds on ice), then the lysate was immunoprecipitated and  after reversion of crosslinking (heat 
treatment for 45 minutes at 75°C), the protein fraction was analyzed by western blot and RNA fraction was amplified 
by RT-PCR. The obtained cDNA was cloned and positive colonies was sequenced to identify the mRNA targets. 
 
In particular, neuronal SH-SY5Y cells were infected with adenoviruses encoding for wild type FUS 
(CLIP-FUS), using as negative control of CLIP experiment SH-SY5Y uninfected cells (CLIP-NEG). After 
24 hours of infection, protein-RNA interactions were fixed on intact cells by treatment with 
formaldehyde 0,5% and then cells were lysed in RIPA buffer, sonicated and immunoprecipitated 
with anti-myc antibody directed against myc epitope in fusion with C-terminal sequence of FUS. As 
shown in figure 30A, after reversion of crosslinks, in the protein fraction, analyzed by western blot, 
FUS protein has been detected. 
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Figure 30: Analysis of protein and RNA fractions after immunoprecipitation of RNA-protein complexes. After reversion 
of crosslinks between RNA and proteins, the presence of FUS in protein fraction, before (Input) and after (IP) the 
immunoprecipitation, was assessed by Western blot analysis using antibody anti-myc (A). As positive control of CLIP 
experiment, the RNA fraction was amplified by RT-PCR with random hexamers and cDNA was subjected a PCR reaction 
to amplify a fragment of about 250bp at C-terminus of FUS sequence (B). 
 
The RNA fraction was amplified by RT-PCR with random hexamers to obtain cDNA. At this point,  
to control the presence of FUS RNA after immunoprecipitation, we made a PCR to amplify a 
fragment of the C-terminus of FUS sequence. Presence of the amplified expected has been found 
only after immunoprecipitation of FUS but not in CLIP-NEG sample (Fig. 30B). 
Then, we went ahead by creating double-stranded DNA (dsDNA) which was phosphorylated and 
cloned into the pBluescript II SK(-) vector. 
Figure 31: A schematic representation of the final steps of CLIP procedure. The dsDNA obtained was subjected to 
Klenow reaction (30 minutes at 25°C) and T4 polymerase reaction (10 minutes at 37°C) with respectively random 
hexamers and dNTPs to generate double strand DNA which was phosphorylated by treatment with T4 polynucleotide 
kinase (30 minutes at 37°C) with ATP as phosphate donor. The fragments of dsDNA obtained were cloned into EcoRV 
restriction site of pBluescript II SK (-) vector and transformed in E.coli DH5α cells. All colonies were grown singularly 
and then plasmid DNA was extracted. The presence of CLIP-insert was analyzed by PCR using T3 and T7 primers, 
empty vectors presented an amplified of 166bp while vector with CLIP-insert present an amplified >166bp. All positive 
samples was sequenced availing an external company. 
  
The recombinant plasmids obtained were transformed in E. coli DH5 cells, all colonies were 
grown individually and then was performed the extraction of the plasmid DNA. Eventual CLIP-
insert present were analyzed by performing a PCR reaction using T3 and T7 primers able to 
discriminate empty vectors from CLIP-insert vectors (Fig. 31). 
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Figure 32: FUS interacts with two human mRNA. A) 19 positive colonies were identified by PCR using T3 and T7 
primers. (-) negative control of PCR reaction; - = empty vector, the amplified 166bp; + = CLIP-insert vector, the 
amplified >166bp. B) Summary table of results of sequence analysis on the 19  positive samples for CLIP-insert. C) The 
two human mRNA which interact with FUS protein. 
 
As shown in figure 32A, 19 positive vectors have been identified for CLIP-insert in CLIP-FUS sample 
by PCR reaction, while it has not been identified any positive vector in CLIP-NEG samples (data not 
shown). These PCR products were subjected to sequence analysis availing an external company 
and only two of these samples showed an alignment with human mRNA (Fig. 32B and 32C): (i) 
Homo sapiens Ribophorin II (RPN2), mRNA. RPN2 is a multi-pass membrane protein localized in 
the endoplasmic reticulum membrane, essential subunit of OST (OligoSaccharylTransferase) 
complex which catalyses the transfer of a high mannose oligosaccharide from a lipid-linked 
oligosaccharide donor to an asparagine residue within an Asn-X-Ser/Thr consensus motif in 
nascent polypeptide chains; (ii) Homo sapiens Peptidase (mitochondrial processing) beta (PMPCB), 
mRNA. PMPCB is an heterodimeric enzyme localized in mitochondrion matrix which cleaves 
presequences (N-terminal transit peptides) from mitochondrial protein precursors, typically with 
Arg in position P2. 
Given the positive results obtained at this point we would have wanted to apply this CLIP method 
on neuronal SH-SY5Y cells infected with adenovirus encoding for FUS with pathological mutations 
ALS associated. But we decided to abandon this aim of my PhD, following the identification of 
global RNA targets for wild type and mutant FUS proteins (FUSR521G and FUSR521H) using PAR-CLIP 
method 257. 
Sonia Esposito                      Physiopathology of ALS: from oxidative stress to RNA metabolism.                                 Pag. 72 
PhD Thesis in Biomolecular and Biotechnological Science 
University of Sassari 
 
We want to emphasize that the mRNAs identified through my CLIP method were also identified in 
the publication above mentioned. 
4.2.1.2 R521G-FUS mutant does not mediates alternative splicing of its mRNA targets. 
In order to evaluate if expression of mutant FUS was able to mediate alternative splicing of its 
mRNA target, we chose to use experimental strategy shown in figure 33. 
 
Figure 33: Experimental strategy to evaluate alternative splicing. 
 
Neuronal cells were infected with recombinant adenoviruses encoding for wild type FUS or with 
pathological mutation R521G. 48 hours after infection, cells were harvested and then was 
extracted total mRNA which was subjected to a semi-quantitative RT-PCR of selected targets, 
RPN2 and PMPCB mRNAs, using primer pairs including the exon-exon junction nearest to binding 
site FUS-mRNA (Fig. 34). 
 
Figure 34: Schematic representation of primer pairs to evaluate alternative splicing. The black arrows depict the 
position of the primers used for RT-PCR. Yellow highlighted sequences indicate FUS binding sites as defined by CLIP-
assay and red boxes define exon-exon junctions. 
 
As shown in figure 35, expression of FUSR521G does not influence alternative splicing of both mRNA 
targets. 
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Figure 35: R521G-FUS mutant does not mediates alternative splicing of its mRNA targets. Semi-quantitative RT-PCR of 
selected targets showing any splice changes in samples with FUS
R521G
 compared to FUS
WT
 and to controls. 
 
4.2.2 Study of the relationship between aggregation, proteins localization, autophagy and cell 
death alterations in the presence of pathological forms of TDP43. 
As stated before, protein aggregation is a key event of all of the major neurodegenerative 
diseases. In recent years, discovery of TDP43 mutations in familial form of ALS and identification of 
TDP43 aggregates as major component in nearly all ALS patients, has led to the hypothesis that 
altered TDP43 function can be a primary cause of the disease. However, the mechanism through 
which TDP43 promotes motor neurons death is still under investigation. To date we know that 
some pathological mutations cause aberrant modification of the protein that generates, for 
proteolysis, a C-terminal fragment of about 25 kDa, and one N-terminal approximately 18 kDa. 
These fragments combine to form cytoplasmic aggregates, resulting in dysfunctions of neuronal 
cells, probably related to loss of function of TDP-43 at the nuclear level 258. 
Several dominantly inherited mutations in TARDBP have been reported in more than one patient 
and by more than one group, which corroborates their causative role in disease pathogenesis 86, 
but it remains to be proved whether these mutants can induce a motor neuronal phenotype and 
to determine the mechanism of toxicity. The aim of this work is the understanding of the 
relationship between TDP43 aggregation/delocalization and neurodegeneration, focusing on 
TDP43 A382T missense mutation responsible for about thirty percent of all ALS cases in Sardinian 
population 93. 
4.2.2.1 TDP43 A382T is delocalized into the cytoplasm. 
In order to get more insight into the pathogenic mechanism of both WT or mutant TDP43 
overexpression (Fig. 36) we perform a more detailed confocal microscopy investigation.  
According to the literature, when TDP43WT is overexpressed, either by transfection or infection, is 
largely localized to the nucleus as well as TDP43M337V mutant. In most cells, however, the A382T 
mutant shows a clear redistribution in the cytoplasm and presents small aggregates both 
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cytoplasmic and intra-nuclear conversely absent in TDP43WT and TDP43M337V. The import defects 
of TDP43A382T is likely to be one of the key steps that are involved in the pathological cascade, and 
that the full blown pathology, namely protein deposition within insoluble inclusions, requires a 
second hit or even multiple hits 259. Since cytoplasmic redistribution of TDP43A382T is more evident 
in transfection experiments (may be due to TDP43 level for single cell) we decided to favor this 
experimental approach instead of infection. In order to test this hypothesis we used a combination 
of a nuclear transport defect (first hit) and cellular stress (second hit) could be necessary to lead to 
the typical TDP-43 pathology. 72 hours post-transfection (first hit) neuronal SH-SY5Y cells were 
subjected to heat shock for 4 hours (second hit). Figure 36B shows that heat shock exacerbate 
TDP43A382T phenotype and big cytoplasmic and intra-nuclear aggregates can be observed. 
Interestingly after the second hit we observed the occurrence of small aggregates also in TDP43WT 
and TDP43M337V mutant. 
 
 
Figure 36: Confocal microscopy analysis of SH-SY5Y cells transfected with human TDP43
WT





. The immunofluorescence was performed after 72 h of transient transfection (A) and after additional 4 
hours of heat shock (B). Antibody anti-myc was used to show the localization of the TDP43 protein and antibody anti-
CREB was used as nuclear marker. The white arrows show the presence of  cytoplasmic and intra-nuclear aggregates. 
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4.2.2.2 Mutation A382T induces shuttling nucleus/cytoplasm. 
To confirm the remarks obtained by immunofluorescence experiments, we extended analysis 
using a biochemical approach to evaluate localization and aggregation properties of wild type and 
mutant TDP43. 
In particular, to investigate the subcellular distribution of wild type and mutant TDP43, 
experiments of cellular fractionation have been carried out. As shown in figure 37, neuronal SH-
SY5Y cells espressing TDP43A382T displayed a significant redistribution of the protein in the 
cytoplasm (red rectangles) when compared to the TDPWT or TDPM337V mutant, which are mostly 
localized in the nuclear fraction. This cytoplasmic accumulation corresponds to its nuclear 
decrease and perhaps in accumulation of its C-terminal fragments of 25kDa, as visible especially in 
total lysate. Similar results were obtained using neuronal SH-SY5Y cells infected with adenoviruses 
encoding for TDP43WT and both mutants analyzed (data not shown). 
 
 
Figure 37: Mutation A382T induces shuttling nucleus/cytoplasm. Cytosolic and nuclear protein extracts were prepared 
after 72 h of transient transfection of SH-SY5Y. The presence of TDP43 protein in cellular fractions (A) and in total 
lysate (B) was assessed by Western blot analysis using antibody anti-TDP43 and anti-myc. Antibody anti-βactin and 
antibody anti-CREB were used respectively as cytoplasmic and nuclear fraction marker. 
 
4.2.2.3 Mutation A382T promotes TDP43 aggregation. 
To better verify the aggregation properties of wild type and mutant TDP43, we transfected 
neuronal SH-SY5Y cells with the indicated plasmids, and the extracted proteins were separated 
according to their solubility. 
As shown in figure 38, it has been observed difference only between TDP43WT and TDP43A382T 
mutant. In fact, as highlighted by red rectangles, TDP43WT and TDP43M337V are mostly present in 
the soluble fraction, almost 50% of TDP43A382T is present in the insoluble fraction. Similar results 
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were obtained using neuronal SH-SY5Y cells infected with adenoviruses encoding for TDP43WT and 
both mutants analyzed (data not shown). 
 
 
Figure 38: Mutation A382T promotes TDP43 aggregation. Total lysate (TOT), Soluble fraction (sol) and insoluble 
fraction (ins) protein were prepared after 72 h of transient transfection of SH-SY5Y cells. The relative abundance of 
TDP43 protein in respective fractions was detected by western blot analysis using antibody anti-TDP43 and anti-myc. 
Antibody anti-βactin was used as a control of protein concentration. 
 
4.2.2.4 Overexpression of WT or mutant TDP43 not induces PARP or LC3 cleavage. 
In order to assess whether the relocation and protein aggregation of TDP43A382T mutant observed 
in previous experiments may be sufficient events to explain cellular toxicity detected by the MTS 
assay, we decided to evaluate activation of different cellular death markers. 
In the first instance, we analyzed possible activation of PARP-1 (poly (ADP-ribose) polymerase-1) 
performing immunofluorescence and western blot experiments on neuronal SH-SY5Y transfected 
cells (data not shown). 
As shown in figure 39B we did not observed any decrease of total PARP-1 in response to 
expression of TDP43WT, TDP43M337V and TDP43A382T in neuronal SH-SY5Y cells when compared to 
SH-SY5Y cells where apoptosis was induced with staurosporine (Fig 39A). This result was 
confirmed by analyzing the level of cleaved PARP-1 in western blot (Fig 39C). 
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The immunofluorescence was performed after 2 h of treatment with STS (staurosporine 1µM) as control positive (A) 
and after 72 h of transient transfection (B). Antibody anti-myc was used to detect the TDP43 protein and antibody 
anti-PARP-1 was used to detect decrease of PARP-1 as apoptotic marker. Western blot analysis on total lysate of SH-
SY5Y cells transfected with human TDP43
WT




, was performed in the same 
experimental conditions indicated in immunofluorescence experiment (C).  Antibody anti-PARP-1 was used to detect 
increase of cleaved-PARP-1 as apoptotic marker.    
 
Finally we decided to verify eventual activation of autophagy performing western blot 
experiments on neuronal SH-SY5Y transfected  with the indicated plasmids to evaluate LC3 
cleavage. 
 
Figure 40: Western blot analysis on total lysate of SH-SY5Y cells after 72 h of transient transfection with human 
TDP43
WT




. Antibody anti-LC3 was used to detect increase of LC3-II levels as 
autophagy marker. 
 
Even in this case we did not observed any increase in LC3-II levels as result of TDP-43WT, 
TDP43M337V and TDP43A382T expression in neuronal SH-SY5Y cells when compared to SH-SY5Y cells 
where autophagy was induced with MG132 (Fig. 40). 
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5.1 ALS cellular models for high-throughput screening (HTS) assay. 
A critical step in designing more effective therapies for the treatment of neurodegenerative 
disorders, such as ALS, is the identification of drugs able to interfere with the first cellular 
alterations, prior to the onset of motoneuronal death. High−throughput experimental strategies 
(HTS) aimed at finding pharmacological compounds that might slow, stop or reverse disease 
progression may provide a unique and powerful tool to identify new active drugs for treating ALS. 
However, such technologies rely on the availability of automated cell-based assays as well as 
screening protocols to fulfill all the requirements needed for HTS procedures. In addition, this kind 
of approach requires the availability of efficient robotic platforms to execute the screening on 
large scale according to high levels of standardization. To this purpose, we have generated 
different cellular models where specific markers of cell toxicity, induced by expression of ALS-
causative genes, may be used as a straightforward read-out for high-throughput screening of 
compound libraries of different nature. In particular, we have developed four different cellular 
models expressing high sensitive fluorescent probes, roGFP, YFPu, DsRed-LC3-GFP and CFP-DEVD-
YFP, suitable for oxidative stress measurement, proteasomal impairment, autophagy defects or 
caspase 3 activation respectively, which have been described to be key-events during ALS disease 
progression. These biological effects have been evaluated upon adenoviral delivery of ALS disease 
causative genes SOD1, FUS and TDP43 in wild type form or with pathological mutations. 
Firstly, we have dealt with generating and characterizing neuronal cell lines stably expressing 
fluorescent reporter genes and we have found that all stable clones, in particular roGFP and YFPu, 
are able to monitor in vivo the redox cellular state, expressed as 405/480 excitation ratio, and the 
ubiquitin-proteasome system activity, expressed as fluorescent accumulation (Fig. 21, 22); further 
experiments will be conducted to evaluate ability of stable clones espressing DsRed-LC3-GFP and 
CFP-DEVD-YFP to monitor in vivo LC3 or caspase-3 activation. 
After production of an high titer of infectious recombinant adenoviruses to drive expression of all 
fALS genes, we carried out several in vivo experiments using different cellular models to monitor 
the biological damage induced by expression of fALS-causative genes. 
5.1.1 Oxidative stress, roGFP and ALS-causative genes. 
A significant body of literature indicates that oxidative stress in neurons is a common marker of 
various adult-onset neurodegenerative diseases including Alzheimer’s Disease (AD), Parkinson’s 
disease (PD) and ALS. The exact mechanisms involved into the events leading to disease initiation 
and progression are still quite obscure, thus preventing the individuation of early and suitable 
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targets for treatment. In fact, despite increasing efforts in research, effective therapies for ND are 
still to be found because of the complexity of pathogenic mechanisms and the nature of cellular 
events initiating the loss of specific neuron populations (cortical, dopaminergic or motor neurons) 
as well as the alteration of neighboring glial cells, which remains a mystery. One of the common 
tracts of the pathological mechanisms underlying ND is an increase of reactive oxygen species 
(ROS). Although the role of ROS in initiating neurodegenerative diseases is still debated, it is 
known that they clearly contribute to events associated with neurodegeneration in different ways 
and they can be used as specific and straightforward markers of the degeneration process. roGFPs 
have been widely used as tools for monitoring neuronal degeneration in the most common NDs. 
roGFP probes were, in fact successfully used to monitor mitochondrial oxidant stress in the 
dopaminergic neurons of the Substantia Nigra, in animal 260,261 and cellular model of PD 262, in 
cellular model for AD 263,264. 
We have demonstrated that stable clones espressing cytoplasmic roGFP or its mitochondrial 
variant mito-roGFP, are able to monitor in vivo oxidative stress induced in cellular environment 
after expression of pathological mutants of ALS causative gene SOD1 (Fig. 25, 26). 
Both WT or mutant TDP43 do not seem to induce oxidative stress measurable by roGFP, while, 
between the FUS mutant tested, only the one bearing the R521G mutation induces oxidation of 
roGFP. This data is of particular interest because underlines that different pathological mutants 
can perturb cellular homeostasis in different ways that are converging on cell death induction. 
5.1.2 Protein aggregation, YFPu and ALS-causative genes. 
A common aspect of different familial forms of ALS, beside a common clinical manifestation, is 
that they all are characterized by genetic mutations leading to misfolding proteins with formation 
of intracellular protein aggregates or inclusions. Misfolded proteins may also delocalize and 
interfere in several ways with the mRNA processing system. 
We tried to monitor the impairment of the degradative ubiquitin-proteasome (UPS) by using a YFP 
fused to the CL1 degron (YFPu), since it has been already used in different paradigms of 
neurodegeneration included ALS 141,248,265-267. 
According to previous reports 141,266,267, we found that YFPu is accumulated in SH-SY5Y cells 
expressing mutant SOD1 (Fig 27C, 28). Moreover we were able to demonstrate also upon mutant 
TDP43 and FUS expression a defect in YFPu clearance (Fig. 27C, 28). By contrast under the same 
experimental conditions we were not able to measure a statistically significant and reproducible 
accumulation of YFPu using a microplates reader. In fact we observed a problematic instrumental 
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evaluation of fluorescence accumulation probably due to the pro-aggregative properties of both 
wild type or mutant FUS and TDP43 (Fig. 27A). 
The YFPu cellular models, although useful to analyse and compare the effects due to fALS causative 
genes expression and to discriminate between different pathological mutants, do not seem to be 
available for HTS assay to perform the screening of a large number of compounds (libraries of 
natural molecules, peptides and pharmacological drugs) and discover new therapeutical 
approaches able to alter the course of ALS. In fact, the system has not proved to be very sensitive 
and it is hard to standardize. 
Recent evidence indicates that endoplasmic reticulum (ER) stress plays a central role in ALS 
pathogenesis. ER stress activates the unfolded protein response (UPR), a homeostatic response to 
misfolded proteins. The UPR has initially a protective effect through up-regulation of specific ER 
stress-regulated genes and inhibition of general protein translation. However, long-term ER stress 
leads to cell death via apoptotic signaling, thus providing a link to neurodegeneration 268. One of 
the mechanisms of ER stress-induced cell death involves induction of CHOP/GADD153 269, a recent 
study has suggested that CHOP expression is a signal required for ER stress-induced cell death 270. 
In the future, we may generate high sensitive probes, previously described, under CHOP-promoter 
control to analyse the effects due to fALS causative genes expression and to obtain a potential cell-
based assay suitable for HTS analysis. 
5.2 TDP43 A382T pathological mutation: relationship between aggregation, localization and cell 
death. 
It has been recently demonstrated that approximately one third of ALS cases on the 
Mediterranean island of Sardinia show a single mutation, namely the c.1144G>A (p.A382T) 
missense mutation, probably due to a founder effect, indicating that these patients had a common 
ancestor and were part of a larger kindred 93,271. It has also been demonstrated a wide phenotypic 
spectrum associated to A382T mutation, spanning from patient with ALS, PD, frontotemporal 
lobar degeneration and neurologically healthy subjects 271,272. Moreover, as stated in the 
introduction, several dominantly inherited mutations in TDP43 in more than one patient and 
identification of TDP43 aggregates as major component in nearly all ALS patients, has led to the 
hypothesis that altered TDP43 function can be a primary cause of disease pathogenesis 86. 
In this respect is of particular interest the possibility of dissecting the pathological mechanisms 
beside the different TDP43 pathological mutants, also to test patient-targeted therapies. 
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Firstly, using SH-SY5Y cell line, we have demonstrated that overexpression of both wild type and 
mutant forms of TDP43 induced a severe reduction of cell proliferation in a dose-dependent 
manner, according with data so far available in literature 120 (Fig. 17C). Immunofluorescence 
experiments have showed that TDP43WT and TDP43M337V mutants, when overexpressed, are largely 
localized to the nucleus, instead the A382T mutant shows a clear cytoplasmic redistribution and 
presents small aggregates both intra-nuclear and cytoplasmic (Fig. 17B, 36A). This phenotype was 
exacerbated when we used a combination of pathological hit (Fig. 36B). 
These remarks have been confirmed through biochemical approaches. In particular, we have 
observed that TDP43WT and TDP43M337V mutant are mostly localized in the nuclear fraction while 
TDP43A382T revealed a significant redistribution in the cytoplasmic fraction that corresponds to its 
nuclear decrease and perhaps in accumulation of its C-terminal fragments of 25kDa (Fig. 37). This 
pro-aggregative ability has been confirmed through solubility assays, where only TDP43A382T has 
displayed a significant accumulation (about 50%) in the insoluble fraction of the proteins, when 
compared to the TDP43WT or TDP43M337V mutants, which are mostly present in the soluble fraction 
(Fig. 38). 
Finally, we have observed that relocation and protein aggregation are events not sufficient to 
induce cell death activation. In particular, we did not observe cleaved PARP-1 or LC3-II 
accumulation in response to expression of TDP-43WT, TDP43M337V and TDP43A382T in neuronal SH-
SY5Y (Fig. 39, 40), to indicate that the observed toxicity does not lead to activation of apoptotic 
pathways or autophagy. 
In conclusion, ALS-linked mutation A382T is itself able to alter the localization and to amplify the 
pro-aggregative ability of TDP43, but the molecular mechanism through which this mutant leads 
to motor neurons degeneration is still not understood. 
We will need further analysis in order to clarify relationship between TDP-43 aggregation, 
inclusion formation and neurodegeneration, since protein aggregation may represent a potential 
therapeutic target for ALS. 
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